

09/ 755,021

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the  
present  
NEWS 4 Jul 15 Data from 1960-1976 added to RDISCLOSURE  
NEWS 5 Jul 21 Identification of STN records implemented  
NEWS 6 Jul 21 Polymer class term count added to REGISTRY  
NEWS 7 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and  
Right Truncation available  
NEWS 8 AUG 05 New pricing for EUROPATFULL and PCTFULL effective  
August 1, 2003  
NEWS 9 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 10 AUG 15 PATDPAFULL: one FREE connect hour, per account, in  
September 2003  
NEWS 11 AUG 15 PCTGEN: one FREE connect hour, per account, in  
September 2003  
NEWS 12 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in  
September 2003  
NEWS 13 AUG 15 TEMA: one FREE connect hour, per account, in  
September 2003  
NEWS 14 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 15 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 16 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right  
Truncation  
NEWS 17 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 18 SEP 22 DIPPR file reloaded  
NEWS 19 SEP 25 INPADOC: Legal Status data to be reloaded  
NEWS 20 SEP 29 DISSABS now available on STN  
  
NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:49:45 ON 03 OCT 2003

09/ 755,021

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.63

0.63

FILE 'REGISTRY' ENTERED AT 09:51:13 ON 03 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2003 HIGHEST RN 596788-60-2

DICTIONARY FILE UPDATES: 1 OCT 2003 HIGHEST RN 596788-60-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 09755021.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 09:51:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 52195 TO ITERATE

100.0% PROCESSED 52195 ITERATIONS

624 ANSWERS

SEARCH TIME: 00.00.02

L2 624 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.78

FILE 'CAPLUS' ENTERED AT 09:51:52 ON 03 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

09/ 755,021

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Oct 2003 VOL 139 ISS 15  
FILE LAST UPDATED: 2 Oct 2003 (20031002/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 37 L2

=> d l3 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 37 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:731098 CAPLUS

TITLE: Alvimopan Adolor/GlaxoSmithKline. [Erratum to document cited in CA138:280633]

AUTHOR(S): Azodo, Ijeoma A.; Ehrenpreis, Eli D.

CORPORATE SOURCE: Gastroenterology Section, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA

SOURCE: Current Opinion in Investigational Drugs (Thomson Current Drugs) (2003), 4(1), 96  
CODEN: COIDAZ; ISSN: 1472-4472

PUBLISHER: Thomson Current Drugs

DOCUMENT TYPE: Journal; General Review; Errata

LANGUAGE: English

AB A review. An erratum.

IT INDEXING IN PROGRESS

IT 156053-89-3, Alvimopan


RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.mu.-opioid receptor antagonist alvimopan for treatment of postoperative ileus and opioid bowel dysfunction in humans (Erratum))

RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L3 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:444233 CAPLUS

DOCUMENT NUMBER: 139:127432

TITLE: Identification of (3R)-7-Hydroxy-N-((1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro-

3-isoquinolinecarboxamide as a Novel Potent and Selective Opioid .kappa. Receptor Antagonist  
AUTHOR(S): Thomas, James B.; Atkinson, Robert N.; Vinson, N. Ariane; Catanzaro, Jennifer L.; Perretta, Carin L.; Fix, Scott E.; Mascarella, S. Wayne; Rothman, Richard B.; Xu, Heng; Dersch, Christina M.; Cantrell, Buddy E.; Zimmerman, Dennis M.; Carroll, F. Ivy

CORPORATE SOURCE: Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, NC, 27709, USA

SOURCE: Journal of Medicinal Chemistry (2003), 46(14), 3127-3137

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB (3R)-7-Hydroxy-N-((1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) was identified as a potent and selective .kappa. opioid receptor antagonist. Structure-activity relation (SAR) studies on JDTic analogs revealed that the 3R,4R stereochem. of the 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine core structure, the 3R attachment of the 7-hydroxy-1,2,3,4-tetrahydroisoquinoline group, and the 1S configuration of the 2-methylpropyl (isopropyl) group were all important to its .kappa. potency and selectivity. The results suggest that, like other .kappa. opioid antagonists such as nor-BNI and GNTI, JDTic requires a second basic amino group to express potent and selective .kappa. antagonist activity in the [35S]GTP.gamma.S functional assay. However, unlike previously reported .kappa. antagonists, JDTic also requires a second phenol group in rigid proximity to this second basic amino group. The potent and selective .kappa. antagonist properties of JDTic can be rationalized using the "message-address" concept wherein the (3R,4R)-3,4-dimethyl-4-(hydroxyphenyl)piperidinyl group represents the message, and the basic amino and phenol group in the N substituent constitutes the address. It is interesting to note the structural commonality (an amino and phenol groups) in both the message and address components of JDTic. The unique structural features of JDTic will make this compd. highly useful in further characterization of the .kappa. receptor.

IT 220124-25-4P 361444-66-8P 441003-77-6P  
441003-78-7P 441003-79-8P 441003-80-1P  
441003-85-6P 569359-83-7P 569359-84-8P  
569359-85-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(identification of tetrahydroisoquinolinecarboxamide deriv. as a novel potent and selective opioid .kappa. receptor antagonist)


RN 220124-25-4 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 361444-66-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441003-77-6 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441003-78-7 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441003-79-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-[(dimethylamino)acetyl]-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441003-80-1 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441003-85-6 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569359-83-7 CAPLUS

CN Benzenepropanamide, .alpha.-amino-4-hydroxy-N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569359-84-8 CAPLUS

CN Benzenepropanamide, .alpha.-amino-4-hydroxy-N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569359-85-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-acetyl-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:341354 CAPLUS

DOCUMENT NUMBER: 139:78276

TITLE: Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies

AUTHOR(S): Kurz, Andrea; Sessler, Daniel I.

CORPORATE SOURCE: Department of Anesthesiology, Outcomes Research Institute, Washington University School of Medicine, St Louis, MO, USA

SOURCE: Drugs (2003), 63(7), 649-671  
CODEN: DRUGAY; ISSN: 0012-6667

PUBLISHER: Adis International Ltd.

DOCUMENT TYPE: Journal; General Review


LANGUAGE: English

AB A review. Opioid treatment for postoperative or chronic pain is frequently assocd. with adverse effects, the most common being dose-limiting and debilitating bowel dysfunction. Postoperative ileus, although attributable to surgical procedures, is often exacerbated by opioid use during and following surgery. Postoperative ileus is marked by increased inhibitory neural input, heightened inflammatory responses, decreased propulsive movements and increased fluid absorption in the gastrointestinal tract. The use of opioids for chronic pain is characterized by a constellation of symptoms including hard dry stools, straining, incomplete evacuation, bloating, abdominal distension and increased gastroesophageal reflux. The current management of opioid-induced bowel dysfunction among patients receiving opioid analgesics consists primarily of nonspecific ameliorative measures. Intensive investigations into the mode of action of opioids have characterized three opioid receptor classes -  $\mu$ ,  $\delta$ ,  $\kappa$  - that mediate the myriad of peripheral and central actions of opioids. Activation of  $\mu$ -opioid receptors in the gastrointestinal tract is responsible for inhibition of gut motility, whereas receptors in the central nervous system mediate the analgesic actions of opioids. Blocking peripheral opioid receptors in the gut is therefore a logical therapeutic target for managing opioid-induced bowel dysfunction. Available opioid antagonists such as naloxone are of limited use because they are readily absorbed, cross the blood-brain barrier, and act at central opioid receptors to reverse analgesia and elicit opioid withdrawal. Methylnaltrexone and alvimopan are recently developed opioid antagonists with activity that is restricted to peripheral receptors. Both have recently shown the ability to reverse opioid-induced bowel dysfunction without reversing analgesia or pptg. central nervous system withdrawal signs in non-surgical patients receiving opioids for chronic pain. In addn., recent clin. studies with alvimopan suggest that it may normalize bowel function without blocking opioid analgesia in abdominal laparotomy patients with opioid-related postoperative ileus.

09/ 755,021

IT 156053-89-3, Alvimopan  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(pathophysiol. and treatment of opioid-induced bowel dysfunction)  
RN 156053-89-3 CAPLUS  
CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-  
piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT: 116 THERE ARE 116 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L3 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2003:145027 CAPLUS  
DOCUMENT NUMBER: 138:280633  
TITLE: Alvimopan Adolor/GlaxoSmithKline  
AUTHOR(S): Azodo, Ijeoma A.; Ehrenpreis, Eli D.  
CORPORATE SOURCE: Gastroenterology Section, Department of Medicine,  
University of Chicago, Chicago, IL, 60637, USA  
SOURCE: Current Opinion in Investigational Drugs (PharmaPress  
Ltd.) (2002), 3(10), 1496-1501  
CODEN: COIDAZ; ISSN: 1472-4472  
PUBLISHER: PharmaPress Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Alvimopan is a potent, peripherally active, .mu.-opioid  
receptor antagonist being developed by Adolor and GlaxoSmithKline (GSK) as  
a potential treatment for post-operative ileus and opioid bowel  
dysfunction [171235], [227431], [241403], [402568].

IT 156053-89-3, Alvimopan  
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of  
action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(.mu.-opioid receptor antagonist alvimopan for treatment of  
postoperative ileus and opioid bowel dysfunction in humans)  
RN 156053-89-3 CAPLUS  
CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-  
piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:521701 CAPLUS

DOCUMENT NUMBER: 137:78865

TITLE: Preparation of tetrahydroisoquinolinyl-alkylaminoalkyl-piperidines as selective kappa opioid receptor ligands  
 INVENTOR(S): Carroll, F. Ivy; Thomas, James B.; Mascarella, S. Wayne

PATENT ASSIGNEE(S): Research Triangle Institute, USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053533	A2	20020711	WO 2002-US482	20020107
WO 2002052533	A3	20020919		



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002132828	A1	20020919	US 2001-755021	20010108
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2001-755021 A 20010108

OTHER SOURCE(S): MARPAT 137:78865

GI



AB Title compds. I [Q = H, CO-alkyl; R1 = alkyl, (alkyl)phenyl, alkyl(heteroaryl), etc.; Y3 = H, OH, Br, Cl, F, CN, CF3, NO2, N3, OR8, CO2R9, etc.; R2 = H, alk(en/yn)yl, CH2-aryl; R3 = H, alk(en/yn)yl, CH2-aryl wherein R2-3 may be bonded together to form a alkyl group; R4 = H, alkyl, carboxy, etc; Z = N, O, S, where Z = O, S, there is no R5; R5 = H, alk(en/yn)yl, CH2-carboxy, etc.; R6 = tetrahydroisoquinolinyl, indazolyl, etc.; X1 = H, alk(en/yn)yl; X2 = H, alk(en/yn)yl or X1-2 together form =O, =S, =NH; R7 = H, alkyl, CH2-aryl; R8 = H, alkyl, CH2-aryl] were prepd. For instance, (+)-(3R,4R)-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine was coupled to Boc-L-valine (THF, BOP, Et3N), the resulting adduct deprotected (CH2Cl2, TFA) and the amide reduced (BH3.bul.SMe2). The resulting intermediate was coupled to (3R)-2-(tert-butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (THF, BOP, Et3N) and deprotected as above to give II. In an assay using human cloned opioid receptors, II had Ki = 0.006 nM for the .kappa.-receptor (compared to nor-BNI Ki = 0.07 nM) and was selective for the kappa receptor with Ki .mu./kappa. = 570 and Ki .delta./kappa. = 16,667. I are useful for the treatment of cocaine or heroine addiction.


IT 361444-66-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug, reactant; prepn. of tetrahydroisoquinolinyl-alkylaminoalkyl-piperidines as selective kappa opioid receptor ligands)

RN 361444-66-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 441003-77-6P 441003-78-7P 441003-79-8P  
441003-80-1P 441003-81-2P 441003-82-3P  
441003-85-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; prepn. of tetrahydroisoquinolinyl-alkylaminoalkyl-piperidines as selective kappa opioid receptor ligands)

RN 441003-77-6 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441003-78-7 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441003-79-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-[(dimethylamino)acetyl]-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 441003-80-1 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441003-81-2 CAPLUS

CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-3-[[[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]amino]methyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441003-82-3 CAPLUS

CN 7-Isoquinolinol, 1,2,3,4-tetrahydro-3-[[[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]amino]methyl]-2-methyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 441003-85-6 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 441003-76-5P 441003-84-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of tetrahydroisoquinolinyl-alkylaminoalkyl-piperidines as selective kappa opioid receptor ligands)

RN 441003-76-5 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-7-hydroxy-3-[[[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441003-84-5 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-7-hydroxy-3-[[[(1S)-1-

09/ 755,021

[[ (3S,4S) -4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:353436 CAPLUS

DOCUMENT NUMBER: 136:369883

TITLE: Preparation of 8-substituted-2,6-methano-3-benzazocines for therapeutic use as opioid receptor agonists

INVENTOR(S): Wentland, Mark P.

PATENT ASSIGNEE(S): Rensselaer Polytechnic Institute, USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036573	A2	20020510	WO 2001-US45581	20011031
WO 2002036573	A3	20030821		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002027135	A5	20020515	AU 2002-27135	20011031
US 2003187009	A1	20031002	US 2002-305287	20021126
PRIORITY APPLN. INFO.:			US 2000-244438P P	20001031
			WO 2001-US45581 W	20011031
OTHER SOURCE(S):		CASREACT 136:369883; MARPAT 136:369883		
GI				



I



II

AB 8-Substituted-2,6-methano-3-benzazocines, such as I [R3 = H, alkyl, alkenyl, aryl, heterocyclyl, cycloalkyl, etc.; R4 = H, OH, NH2, alkoxy, hydroxyalkyl, etc.; R5, R6 = alkyl; A = CH2OH, CH2SH, CH2NH2, carboxy, carboxamido, thiocarboxamido, etc.; X = H2, O], were prepd. for pharmaceutical use as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. Thus, benzazocine II (A = CN) was prepd. in 80% yield by reaction of triflate II (A = OSO2CF3) and Zn(CN)2 in DMF using Pd(PPh3)4. The prepd. benzazocines were tested for opioid receptor binding activity in mice, e.g. with II (A = CONH2) giving Ki values of 0.41 +/- 0.07, 8.3 +/- 0.49 and 0.53 +/- 0.06 nM for the .mu., .delta. and .kappa. opioid receptors, resp. The 8-carboxamides, thiocarboxamides, hydroxyamides and formamides were preferred.

IT 156130-44-8P 361444-66-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 8-substituted-2,6-methano-3-benzazocines for therapeutic use as opioid receptor agonists)

RN 156130-44-8 CAPLUS

CN Glycine, N-[(2R)-2-[[[(3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 361444-66-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:142675 CAPLUS

DOCUMENT NUMBER: 136:200104

TITLE: Preparation of 4-(3,4-dihydroxyphenyl)piperidine diethers derivatives as inhibitors of phosphodiesterase 4 (PDE4) and drugs containing these derivatives as the active ingredient

INVENTOR(S): Nakai, Hisao; Kishikawa, Katsuya

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014280	A1	20020221	WO 2001-JP6861	20010809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001077738	A5	20020225	AU 2001-77738	20010809
EP 1308440	A1	20030507	EP 2001-955627	20010809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013167	A	20030624	BR 2001-13167	20010809
JP 3433752	B2	20030804	JP 2002-519423	20010809
NO 2003000639	A	20030409	NO 2003-639	20030207
PRIORITY APPLN. INFO.:				
			JP 2000-243881	A 20000811
			JP 2000-357517	A 20001124
			WO 2001-JP6861	W 20010809

OTHER SOURCE(S): MARPAT 136:200104

GI




AB The title compds. [I; R1 = H, cyano; R2, R3 = H, C1-8 alkyl, C3-7 cycloalkyl, C3-7-cycloalkyl-C1-8 alkyl, C1-8 alkyl substituted by 1-3 halogen atoms, phenyl-C1-8 alkyl, C1-8 alkoxy-C1-8 alkyl, Q (where n = 1-5); R4, R5 = H, C1-8 alkyl or CR4R5 represents a satd. C3-7 carbocyclic ring; R6 = OH, C1-8 alkoxy, NHOH, Ph-C1-8 alkoxy; m = an integer of 1-4] or nontoxic salts thereof are prepd. Because of having a PDE4 inhibitory activity, the compds. I are useful in preventing and/or treating inflammatory diseases (asthma, obstructive pulmonary diseases, septicemia, sarcoidosis, nephritis, hepatitis, or enteritis), diabetic diseases, allergic diseases (allergic rhinitis, allergic conjunctivitis, or atopic dermatitis), autoimmune diseases (ulcerative colitis, Crohn's disease, rheumatism, psoriasis, multiple sclerosis, or collagen disease), osteoporosis, bone fracture, obesity, depression, Parkinson's disease, dementia, ischemic reperfusion disorder, leukemia, or AIDS. Thus, a mixt. of 239 mg 2-[4-(3-cyclopentyloxy-4-methoxyphenyl)-4-cyanopiperidin-1-yl]acetic acid, 192 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 4 mL DMF, and 0.35 mL (1-methoxy-1-methylethyl)oxyamine was stirred at room temp. for 3 h to give 289 mg N-(1-methoxy-1-methylethoxy)-2-[4-(3-cyclopentyloxy-4-methoxyphenyl)-4-cyanopiperidin-1-yl]acetamide which (280 mg) was stirred with a mixt. of 3 mL MeOH and 0.35 mL 2 N HCl at room temp. for 1 h to give 189 mg N-hydroxy-2-[4-(3-cyclopentyloxy-4-methoxyphenyl)-4-cyanopiperidin-1-yl]acetamide hydrochloride (II). II showed IC50 of 0.03 nM against human PDE4 from human monocyte U937 cell. A tablet and an ampule formulation contg. II were described.

IT **401519-03-7P**, 2-[4-(3-Hydroxy-4-methoxyphenyl)-4-cyanopiperidin-1-yl]acetic acid ethyl ester  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of 4-(3,4-dihydroxyphenyl)piperidine diethers derivs. as inhibitors of phosphodiesterase 4 (PDE4) for therapeutic agents)

RN 401519-03-7 CAPLUS

CN 1-Piperidineacetic acid, 4-cyano-4-(3-hydroxy-4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:2292 CAPLUS

DOCUMENT NUMBER: 137:134182

TITLE: Alvimopan (ADL 8-2698) Is a Novel Peripheral Opioid Antagonist

AUTHOR(S): Schmidt, William K.  
 CORPORATE SOURCE: Adolor Corporation, Exton, PA, 19341-1127, USA  
 SOURCE: American Journal of Surgery (2001), 182(5A), 27S-38S  
 CODEN: AJSUAB; ISSN: 0002-9610  
 PUBLISHER: Excerpta Medica, Inc.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review. Alvimopan (ADL 8-2698; Adolor Corporation, Exton, PA, USA) is a novel, peripherally restricted opioid antagonist. After oral administration, it has activity specific to the gastrointestinal (GI) tract. ADL 8-2698 has low systemic absorption and a high affinity for  $\mu$ -opioid receptors. In healthy subjects, ADL 8-2698 antagonized loperamide-induced changes in GI transit and prevented morphine-induced delays in oral-cecal transit time without antagonizing centrally mediated opioid effects, such as analgesia or pupillary constriction. In the treatment of opioid naive patients who underwent surgery and received opioids for acute pain, oral ADL 8-2698 (6.0 mg) improved the management of postoperative ileus (POI) by shortening the time to achieve normal bowel function and, ultimately, hospital stay. Postoperative nausea and vomiting and the overall incidence of all GI side effects were reduced in patients treated with ADL 8-2698 for POI. Analgesia was not compromised, because there were no changes in median opioid consumption or Visual Analog Scale (VAS) pain scores in patients treated with ADL 8-2698 vs. patients treated with placebo. No drug-related side effects were obsd. in acute pain postsurgical patients in the initial POI study. In patients treated with opioids for chronic pain or opioid addiction, lower doses of oral ADL 8-2698 (0.5 to 3.0 mg) reversed opioid bowel dysfunction (OBD) and normalized GI activity. These effects were evident without compromising opioid analgesia or inducing central nervous system symptoms of withdrawal. Some chronic opioid patients receiving apparently supramaximal doses of ADL 8-2698 ( $>3.0$  mg) reported localized GI side effects, possibly indicative of a localized GI withdrawal response. The most common side effects of ADL 8-2698 in chronic pain patients with OBD were abdominal pain, flatulence, and diarrhea. These effects were not obsd. in most OBD patients receiving lower doses of ADL 8-2698. Overall, ADL 8-2698 was well tolerated in clin. trials. Further studies to evaluate the efficacy and safety of ADL 8-2698 in clin. practice are in progress.


IT 156053-89-3, Alvimopan

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alvimopan is novel peripheral opioid antagonist used in treatment of opioid related gastrointestinal side effects)

RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


09/ 755,021

L3 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2001:869020 CAPLUS  
DOCUMENT NUMBER: 136:677  
TITLE: Novel methods and compositions involving opioids and antagonists thereof  
INVENTOR(S): Farrar, John J.  
PATENT ASSIGNEE(S): Farrar, John, USA  
SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 304,199, abandoned.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001047005	A1	20011129	US 2000-725661	20001129
US 6451806	B2	20020917		

PRIORITY APPLN. INFO.: US 2000-304199 B2 20000427  
OTHER SOURCE(S): MARPAT 136:677  
AB Novel methods and compns. comprising opioids and opioid antagonists. In preferred embodiments, the methods and compns. comprise opioids and peripheral mu opioid antagonist compds. The methods and compns. are particularly suitable for treating and/or preventing side effects assocd. with opioids including, for example, constipation, vomiting and/or nausea.  
IT **156053-89-3**  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prevention and treatment of opioid side effects with .mu.-opioid antagonists)  
RN 156053-89-3 CAPLUS  
CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L3 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2001:798759 CAPLUS  
DOCUMENT NUMBER: 135:339259  
TITLE: Methods using .mu. opioid antagonist compounds for the treatment and prevention of ileus  
INVENTOR(S): Farrar, John J.; Schied, Peter J.; Schmidt, William K.; Carpenter, Randall L.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Provisional Ser. No. 287,560, abandoned.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent



09/ 755,021

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001036951	A1	20011101	US 2000-725708	20001129
US 6469030	B2	20021022		
US 2002188005	A1	20021212	US 2002-171299	20020613
PRIORITY APPLN. INFO.:			US 2000-287560P P	20000427
			US 2000-725708 A3	20001129

OTHER SOURCE(S): MARPAT 135:339259

AB Methods are disclosed for the treatment and/or prevention of ileus. The methods may comprise administering to a patient an effective amt. of a peripheral .mu. opioid antagonist compd. Preferred compds. for use in the methods include piperidine-N-alkylcarboxylates, quaternary morphinans, opium alkaloid derivs. and quaternary benzomorphans. The methods are particularly suitable for treating and/or preventing postsurgical ileus and postpartum ileus.

IT 371154-35-7 371154-36-8 371154-37-9  
371154-38-0 371154-39-1 371154-40-4  
371154-41-5 371154-42-6 371154-43-7  
371154-44-8 371154-45-9 371154-46-0  
371154-47-1 371154-48-2 371154-49-3  
371154-50-6 371154-51-7 371154-52-8  
371154-53-9 371154-54-0 371154-55-1  
371154-56-2 371154-57-3 371154-58-4  
371154-65-3 371155-97-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.mu. opioid antagonist compds. for treatment and prevention of ileus)

RN 371154-35-7 CAPLUS

CN Glycine, N-[3-cyclohexyl-2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidiny]methyl]-1-oxopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371154-36-8 CAPLUS

CN .beta.-Alanine, N-[3-cyclohexyl-2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidiny]methyl]-1-oxopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




09/ 755,021

RN 371154-37-9 CAPLUS

CN 1-Piperidinepropanamide, N-(3-amino-3-oxopropyl)-.alpha.-(cyclohexylmethyl)-4-(2-hydroxyphenyl)-3,4-dimethyl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371154-38-0 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371154-39-1 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 371154-40-4 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-4-(2-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

09/ 755,021


Relative stereochemistry.



RN 371154-41-5 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(dimethylamino)-2-oxoethyl]-4-(2-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 371154-42-6 CAPLUS

CN 1-Piperidinepropanamide, 4-(2-hydroxyphenyl)-3,4-dimethyl-N-[2-[(1-methylethyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 371154-43-7 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 371154-44-8 CAPLUS  
CN .beta.-Alanine, N-[2-[[ (3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



RN 371154-45-9 CAPLUS  
CN .beta.-Alanine, N-[2-[[ (3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371154-46-0 CAPLUS  
CN 1-Piperidinepropanamide, N-[3-(ethylamino)-3-oxopropyl]-4-(2-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 371154-47-1 CAPLUS  
CN 1-Piperidinepropanamide, 4-(2-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371154-48-2 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371154-49-3 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methoxy-2-oxoethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 371154-50-6 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, pentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371154-51-7 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(methylamino)-2-oxoethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371154-52-8 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-oxo-2-[(phenylmethyl)amino]ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 371154-53-9 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-(acetyloxy)ethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371154-54-0 CAPLUS  
CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371154-55-1 CAPLUS  
CN Glycine, N-[(2R)-2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021




RN 371154-56-2 CAPLUS  
CN Glycine, N-[(2S)-2-[[[(3S,4S)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 371154-57-3 CAPLUS  
CN Glycine, N-[(2R)-2-[[[(3S,4S)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 371154-58-4 CAPLUS  
CN 1-Piperidinepropanamide, 4-(2-hydroxyphenyl)-3,4-dimethyl-N-[2-oxo-2-[(phenylmethyl)amino]ethyl]-.alpha.-(phenylmethyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 371154-65-3 CAPLUS  
 CN Glycine, N-[(2R)-2-[[[(3S,4S)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 371155-97-4 CAPLUS  
 CN Glycine, N-[2-[[[(3R,4R)-4-(2-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 4-methoxycyclohexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:733273 CAPLUS  
 DOCUMENT NUMBER: 136:63982  
 TITLE: Selective postoperative inhibition of gastrointestinal opioid receptors  
 AUTHOR(S): Taguchi, Akiko; Sharma, Neeru; Saleem, Rao M.; Sessler, Daniel I.; Carpenter, Randall L.; Seyedsadr, Mahmoud; Kurz, Andrea  
 CORPORATE SOURCE: Dep. Anesthesiology, Washington Univ., St. Louis, MO, 63110, USA  
 SOURCE: New England Journal of Medicine (2001), 345(13),

935-940

CODEN: NEJMAG; ISSN: 0028-4793

PUBLISHER:

Massachusetts Medical Society

DOCUMENT TYPE:

Journal

LANGUAGE:

English

**AB** Postoperative recovery of gastrointestinal function and resumption of oral intake are crit. determinants of the length of hospital stay. Although opioids are effective treatments for postoperative pain, they contribute to the delayed recovery of gastrointestinal function. We studied the effects of ADL 8-2698, an investigational opioid antagonist with limited oral absorption that does not readily cross the blood-brain barrier, on postoperative gastrointestinal function and the length of hospitalization. We randomly assigned 79 patients - including 1 whose surgery was canceled - to receive one capsule contg. 1 mg or 6 mg of ADL 8-2698 or an identical-appearing placebo capsule two hours before major abdominal surgery and then twice daily until the first bowel movement or until discharge from the hospital. Data were analyzed for 26 patients in each of the three groups; all received opioids for postoperative pain relief. Observers who were unaware of the group assignments evaluated the outcomes. Fifteen patients underwent partial colectomy and 63 underwent total abdominal hysterectomy. Patients given 6 mg of ADL 8-2698 had significantly faster recovery of gastrointestinal function than those given placebo. The median time to the first passage of flatus decreased from 70 to 49 h ( $P = 0.03$ ), the median time to the first bowel movement decreased from 111 to 70 h ( $P = 0.01$ ), and the median time until patients were ready for discharge decreased from 91 to 68 h ( $P = 0.03$ ). Effects in the group that received 1 mg of ADL 8-2698 were less pronounced. Selective inhibition of gastrointestinal opioid receptors by an antagonist with limited oral absorption that does not readily cross the blood-brain barrier speeds recovery of bowel function and shortens the duration of hospitalization.


**IT** 156053-89-3, ADL 8-2698

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (selective postoperative inhibition of gastrointestinal opioid receptors)

**RN** 156053-89-3 CAPLUS

**CN** Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT:

26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:510739 CAPLUS

DOCUMENT NUMBER: 135:251896

TITLE: Identification of the first trans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid .kappa.

receptor antagonist activity

AUTHOR(S): Thomas, James B.; Atkinson, Robert N.; Rothman, Richard B.; Fix, Scott E.; Mascarella, S. Wayne; Vinson, N. Ariane; Xu, Heng; Dersch, Christina M.; Lu, Y. -F.; Cantrell, Buddy E.; Zimmerman, Dennis M.; Carroll, F. Ivy

CORPORATE SOURCE: Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, NC, 27709, USA

SOURCE: Journal of Medicinal Chemistry (2001) 44(17), 2687-2690


CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB A structurally novel opioid .kappa. receptor selective ligand has been identified. This compd., (3R)-7-hydroxy-N-((1S)-1-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, I) demonstrated high affinity for the .kappa. receptor in the binding assay (.kappa.  $K_i$  = 0.3 nM) and highly potent and selective .kappa. antagonism in the [35S]GTP-.gamma.-S assay using cloned opioid receptors (.kappa.  $K_i$  = 0.006 nM, .mu./ .kappa. ratio = 570, .delta./ .kappa. ratio > 16600).


IT 220124-25-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(identification of trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine deriv. as highly potent and selective opioid .kappa. receptor antagonist)

RN 220124-25-4 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 361444-66-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (identification of trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine deriv. as highly potent and selective opioid .kappa. receptor antagonist)

RN 361444-66-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:435040 CAPLUS

DOCUMENT NUMBER: 135:29144

TITLE: Methods using a peripheral .mu. opioid antagonist for the treatment and prevention of ileus

INVENTOR(S): Farrar, John J.; Schied, Peter J.; Schmidt, William K.; Carpenter, Randall L.

PATENT ASSIGNEE(S): Adolor Corporation, USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042207	A2	20010614	WO 2000-US42313	20001129
WO 2001042207	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001039705	A5	20010618	AU 2001-39705	20001129
EP 1244448	A2	20021002	EP 2000-992255	20001129
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003517476	T2	20030527	JP 2001-543508	20001129
PRIORITY APPLN. INFO.:			US 1999-450920	A 19991129
			WO 2000-US42313	W 20001129

09/ 755,021

OTHER SOURCE(S): MARPAT 135:29144

AB Methods are provided for the treatment and/or prevention of ileus. The methods may comprise administering to a patient an effective amt. of a peripheral .mu. opioid antagonist compd. Preferred compds. for use in the methods include piperidine-N-alkylcarboxylates, quaternary morphinans, opium alkaloid derivs. and quaternary benzomorphans. The methods are particularly suitable for treating and/or preventing postsurgical ileus and postpartum ileus.

IT 145590-95-0 145603-86-7 145603-87-8  
145603-88-9 156053-89-3 342638-95-3  
342638-96-4 342638-98-6 342639-00-3  
342639-02-5 342639-04-7 342639-06-9  
342639-08-1 342639-10-5 342639-12-7  
342639-14-9 342639-16-1 342639-18-3  
342639-20-7 342639-22-9 342639-25-2  
342639-27-4 342639-30-9 342639-32-1  
342639-41-2 342646-98-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peripheral .mu. opioid antagonist for treatment and prevention of ileus)

RN 145590-95-0 CAPLUS

CN Glycine, N-[(2R)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145603-86-7 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021



RN 145603-87-8 CAPLUS  
CN Glycine, N-[(2R)-2-[[ (3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 145603-88-9 CAPLUS  
CN Glycine, N-[(2S)-2-[[ (3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 342638-95-3 CAPLUS

CN Glycine, N-[3-cyclohexyl-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342638-96-4 CAPLUS

CN .beta.-Alanine, N-[3-cyclohexyl-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 342638-98-6 CAPLUS  
CN 1-Piperidinepropanamide, N-(3-amino-3-oxopropyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



RN 342639-00-3 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-02-5 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




09/ 755,021



RN 342639-04-7 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-06-9 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(dimethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-08-1 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(1-methylethyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-10-5 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-12-7 CAPLUS

CN .beta.-Alanine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-14-9 CAPLUS

CN .beta.-Alanine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-16-1 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 342639-18-3 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-20-7 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-22-9 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methoxy-2-oxoethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-25-2 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, pentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-27-4 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(methylamino)-2-oxoethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 342639-30-9 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-oxo-2-[(phenylmethyl)amino]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-32-1 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-(acetyloxy)ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-41-2 CAPLUS  
CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-oxo-2-[(phenylmethyl)amino]ethyl]-.alpha.-(phenylmethyl)-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342646-98-4 CAPLUS  
 CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 4-methoxycyclohexyl ester  
 (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:434812 CAPLUS  
 DOCUMENT NUMBER: 135:29160  
 TITLE: Methods using peripheral .mu. opioid antagonists for the treatment and prevention of dizziness and pruritus  
 INVENTOR(S): Carpenter, Randall L.  
 PATENT ASSIGNEE(S): Adolor Corporation, USA  
 SOURCE: PCT Int. Appl., 50 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041705	A2	20010614	WO 2000-US42310	20001129
WO 2001041705	A3	20011220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041369	A5	20010618	AU 2001-41369	20001129
PRIORITY APPLN. INFO.:			US 1999-450812	A 19991129
			WO 2000-US42310	W 20001129

09/ 755,021

OTHER SOURCE(S): MARPAT 135:29160

AB Methods are provided for the treatment and/or prevention of dizziness and/or pruritus. The methods may comprise administering to a patient an effective amt. of a peripheral .mu. opioid antagonist compd. Preferred compds. for use in the methods include piperidine-N-alkylcarboxylates, quaternary morphinans, opium alkaloid derivs. and quaternary benzomorphans. The methods are particularly suitable for treating and/or preventing dizziness and/or pruritus assocd. with opioid compds.

IT 145590-95-0 145603-86-7 145603-87-8  
145603-88-9 156053-89-3 342638-95-3  
342638-96-4 342638-98-6 342639-00-3  
342639-02-5 342639-04-7 342639-06-9  
342639-08-1 342639-10-5 342639-12-7  
342639-14-9 342639-16-1 342639-18-3  
342639-20-7 342639-22-9 342639-25-2  
342639-27-4 342639-30-9 342639-32-1  
342639-41-2 342646-98-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peripheral .mu. opioid antagonist for treatment and prevention of dizziness and pruritus)

RN 145590-95-0 CAPLUS

CN Glycine, N-[(2R)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145603-86-7 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021



RN 145603-87-8 CAPLUS  
CN Glycine, N-[(2R)-2-[[ (3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145603-88-9 CAPLUS  
CN Glycine, N-[(2S)-2-[[ (3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 342638-95-3 CAPLUS

CN Glycine, N-[3-cyclohexyl-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342638-96-4 CAPLUS

CN .beta.-Alanine, N-[3-cyclohexyl-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 342638-98-6 CAPLUS  
CN 1-Piperidinepropanamide, N-(3-amino-3-oxopropyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



RN 342639-00-3 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-02-5 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-04-7 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-06-9 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(dimethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-08-1 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(1-methylethyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-10-5 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-12-7 CAPLUS

CN .beta.-Alanine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-14-9 CAPLUS

CN .beta.-Alanine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 342639-16-1 CAPLUS  
CN 1-Piperidinepropanamide, N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



RN 342639-18-3 CAPLUS  
CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-20-7 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-22-9 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methoxy-2-oxoethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-25-2 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, pentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-27-4 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(methylamino)-2-oxoethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-30-9 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-oxo-2-[(phenylmethyl)amino]ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-32-1 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-(acetyloxy)ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-41-2 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-oxo-2-[(phenylmethyl)amino]ethyl]-.alpha.-(phenylmethyl)-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342646-98-4 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 4-methoxycyclohexyl ester  
(9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:396624 CAPLUS  
 DOCUMENT NUMBER: 135:14336  
 TITLE: Compositions containing opioids and their antagonists  
 INVENTOR(S): Farrar, John J.  
 PATENT ASSIGNEE(S): Adolor Corporation, USA  
 SOURCE: PCT Int. Appl., 103 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037785	A2	20010531	WO 2000-US42315	20001129
WO 2001037785	A3	20020110		
WO 2001037785	C2	20020829		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001039706	A5	20010604	AU 2001-39706	20001129
EP 1244447	A2	20021002	EP 2000-992256	20001129

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,



09/ 755,021

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
JP 2003528819 T2 20030930 JP 2001-539402 20001129  
PRIORITY APPLN. INFO.: US 1999-450806 A 19991129  
WO 2000-US42315 W 20001129

OTHER SOURCE(S): MARPAT 135:14336

AB Methods and compns. comprise opioids and opioid antagonists, e.g., peripheral .mu.-opioid antagonists. Methods and compns. are particularly suitable for treating and/or preventing side effects (assocd. with opioids) such as e.g., constipation, vomiting and/or nausea.

IT 145590-95-0 145603-86-7 145603-87-8  
145603-88-9 156053-89-3 342638-95-3  
342638-96-4 342638-98-6 342639-00-3  
342639-02-5 342639-04-7 342639-06-9  
342639-08-1 342639-10-5 342639-12-7  
342639-14-9 342639-16-1 342639-18-3  
342639-20-7 342639-22-9 342639-25-2  
342639-27-4 342639-30-9 342639-32-1  
342639-35-4 342639-41-2 342646-98-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. contg. opioids and their antagonists)

RN 145590-95-0 CAPLUS

CN Glycine, N-[(2R)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145603-86-7 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145603-87-8 CAPLUS

CN Glycine, N-[(2R)-2-[[ (3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145603-88-9 CAPLUS

CN Glycine, N-[(2S)-2-[[ (3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 342638-95-3 CAPLUS

CN Glycine, N-[3-cyclohexyl-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342638-96-4 CAPLUS

CN .beta.-Alanine, N-[3-cyclohexyl-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 342638-98-6 CAPLUS  
CN 1-Piperidinepropanamide, N-(3-amino-3-oxopropyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



RN 342639-00-3 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-02-5 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-04-7 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-06-9 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(dimethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-08-1 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(1-methylethyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 342639-10-5 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 342639-12-7 CAPLUS  
CN .beta.-Alanine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-14-9 CAPLUS  
CN .beta.-Alanine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 342639-16-1 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 342639-18-3 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-.alpha.-(phenylmethyl)-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-20-7 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021




RN 342639-22-9 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methoxy-2-oxoethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 342639-25-2 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, pentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 342639-27-4 CAPLUS  
CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(methylamino)-2-oxoethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




09/ 755,021



RN 342639-30-9 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-oxo-2-[(phenylmethyl)amino]ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-32-1 CAPLUS

CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-(acetyloxy)ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 342639-35-4 CAPLUS


CN Glycine, N-[(2R)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 342639-41-2 CAPLUS  
 CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-oxo-2-  
 [(phenylmethyl)amino]ethyl]-.alpha.-(phenylmethyl)-, (3R,4R)- (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 342646-98-4 CAPLUS  
 CN Glycine, N-[2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-  
 piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 4-methoxycyclohexyl ester  
 (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:102913 CAPLUS  
 DOCUMENT NUMBER: 135:117075  
 TITLE: ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl)  
 piperidine, prevents gastrointestinal effects of  
 intravenous morphine without affecting analgesia  
 AUTHOR(S): Liu, Spencer S.; Hodgson, Peter S.; Carpenter, Randall  
 L.; Fricke, James R., Jr.  
 CORPORATE SOURCE: Departments of Anesthesiology, Virginia Mason Medical  
 Center, The University of Washington, Seattle, WA, USA  
 SOURCE: Clinical Pharmacology & Therapeutics (St. Louis, MO,

United States) (2001), 69(1), 66-71

CODEN: CLPTAT; ISSN: 0009-9236

PUBLISHER:

Mosby, Inc.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and i.v. placebo, oral placebo and i.v. morphine (0.05 mg .cntdot. kg-1), and oral ADL 8-2698 (4 mg) and i.v. morphine (0.05 mg .cntdot. kg-1) in a double blind, cross-over study. Morphine prolonged gastrointestinal transit time from 69 to 103 min (P = .005); this was prevented by ADL 8-2698 (P = .004). Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and i.v. morphine (0.15 mg/kg) or to receive oral and i.v. placebo. Analgesia and pupil constriction were measured. Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002). We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid antagonism without affecting central opioid analgesia.

IT 156053-89-3, ADL 8-2698 170098-38-1


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ADL 8-2698 trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine prevents gastrointestinal effects of i.v. morphine without affecting analgesia)

RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 170098-38-1 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, dihydrate (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

● 2 H<sub>2</sub>O

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2001:56872 CAPLUS  
 DOCUMENT NUMBER: 134:100768  
 TITLE: Preparation of 4-arylpiperidines and their use for treatment of pruritus  
 INVENTOR(S): Gibson, Stephen Paul; Tommasini, Ivan  
 PATENT ASSIGNEE(S): Pfizer Inc., USA  
 SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001019672	A2	20010123	JP 2000-157620	20000529
JP 3437819	B2	20030818		
EP 1072595	A2	20010131	EP 2000-304226	20000518
EP 1072595	A3	20010214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6518282	B1	20030211	US 2000-576780	20000523
CA 2309475	AA	20001128	CA 2000-2309475	20000526
BR 2000002516	A	20010102	BR 2000-2516	20000529
PRIORITY APPLN. INFO.:			GB 1999-12415	A 19990528
OTHER SOURCE(S):	MARPAT 134:100768			
GI				



I

AB Title compds. I [R1, R2= H, C1-4 alkyl; R3 = (un)substituted aryl, C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.; R4 = H, C1-5 alkyl, C1-12 alkanoyl, (pyridin-3-yl)carbonyl, (pyridin-4-yl)carbonyl, etc.] and their pharmaceutically and veterinarily acceptable derivs. are prepd. 2-(Cyclohexyloxy)ethyl 4-methylbenzenesulfonate was reacted with (.-.-.)-3-(trans-3,4-dimethylpiperidinyl)phenol in PhMe in the presence of pyridine under reflux for 3 h to give 31% (.-.-.)-3-[1-[2-(cyclohexyloxy)ethyl]-trans-3,4-dimethylpiperidinyl]phenol.

IT 318958-14-4P 318958-16-6P 318958-19-9P  
318958-22-4P 318958-26-8P 318958-36-0P  
318958-38-2P 318958-43-9P 318958-44-0P  
318958-45-1P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylpiperidines for treatment of pruritus)

RN 318958-14-4 CAPLUS

CN Phenol, 3-[(3R,4S)-3,4-dimethyl-1-[3-(2-propenyloxy)propyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 318958-16-6 CAPLUS

CN Phenol, 3-[(3R,4S)-1-(2-ethoxyethyl)-3,4-dimethyl-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




09/ 755,021

RN 318958-19-9 CAPLUS

CN Phenol, 3-[(3R,4S)-1-[2-(2-methoxyethoxy)ethyl]-3,4-dimethyl-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 318958-22-4 CAPLUS

CN Phenol, 3-[(3R,4S)-1-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]-3,4-dimethyl-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 318958-26-8 CAPLUS

CN Phenol, 3-[(3R,4S)-1-[2-(2-hydroxyethoxy)ethyl]-3,4-dimethyl-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 318958-36-0 CAPLUS

CN Phenol, 3-[(3R,4S)-3,4-dimethyl-1-[2-(1-methylethoxy)ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




09/ 755,021

RN 318958-38-2 CAPLUS

CN Phenol, 3-[(3R,4S)-3,4-dimethyl-1-(2-propoxyethyl)-4-piperidinyl]-, rel-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 318958-43-9 CAPLUS

CN Phenol, 3-[(3R,4S)-1-[2-(ethylthio)ethyl]-3,4-dimethyl-4-piperidinyl]-, rel-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 318958-44-0 CAPLUS

CN Phenol, 3-[(3R,4S)-1-[2-(ethylsulfinyl)ethyl]-3,4-dimethyl-4-piperidinyl]-, rel-  
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 318958-45-1 CAPLUS


CN Phenol, 3-[(3R,4S)-1-[2-(ethylsulfonyl)ethyl]-3,4-dimethyl-4-piperidinyl]-, rel-  
(9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2000:631890 CAPLUS  
 DOCUMENT NUMBER: 133:222737  
 TITLE: Preparation of 4-phenyl-4-heteroarylpiperidines as  
 ligands for opioid receptors  
 INVENTOR(S): Liras, Spiros; McHardy, Stanton Furst  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: Jpn. Kokai Tokkyo Koho, 34 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000247969	A2	20000912	JP 2000-44911	20000222
JP 3370038	B2	20030127		
EP 1038872	A1	20000927	EP 2000-300974	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6444679	B1	20020903	US 2000-503679	20000214
CA 2299036	AA	20000822	CA 2000-2299036	20000221
BR 2000000901	A	20010821	BR 2000-901	20000222
PRIORITY APPLN. INFO.:			US 1999-121156P	P 19990222
OTHER SOURCE(S):	MARPAT 133:222737			
GI				



I

AB The title compds. [I; X, Y = O, N, S, CH; provided that the ring contg. X and Y is arom. and both X and Y are not simultaneously O or S; n = 0,1; R1 = H, C0-8 alkoxy-C0-8 alkyl (a total C atoms being .ltoreq.8), aryl, aryl-C1-8 alkyl, heteroaryl, heteroaryl-C1-8 alkyl, heterocyclyl, heterocyclyl-C1-8 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-8 alkyl, etc.; R2 = H, aryl, halo, heteroaryl, heterocyclyl, SO2R4, COR4, CONR5R6, CO2R4, C(OH)R5R6, etc.; wherein R4, R5, or R6 is selected from group



defined in R1 or R5 and R6 together with bonded N or C atom form 3 to 7-membered ring contg. 0-3 heteroatoms selected from O, N, and S; R3 = HO, hydroxy-C1-6 alkyl, C1-6 alkyl-C1-6 alkoxy, NHSO2R7, C(OH)R7R8, halo, heteroaryl, CONHR7; R7, R8 = H, C1-4 alkyl, C1-4 alkoxy, or C1-4 alkoxy-C1-4 alkyl, wherein each alkyl is optionally substituted with 1-7 F atom(s); Z1 = H, halo, C1-5 alkyl; provided that two-adjacent ring oxygen or nitrogen atoms or ring O atom adjacent to ring S atom do not exist in heterocyclic or heteroaryl portion] are prepd. These compds. regulate bindings to opioid receptors and are useful for the improvement, prevention, or treatment of various disorders or conditions, e.g. (1) inflammatory diseases such as arthritis, psoriasis, and asthma, (2) disorders of respiratory function such as asthma, coughing, and apnea (breathlessness), (3) allergy, (4) gastrointestinal disorders such as gastritis, functional intestinal disorders, irritable bowel syndromes, functional diarrhea, functional dilation, functional pain, indigestion not forming peptic ulcer, gastrointestinal motility disorders, and vomiting, (5) stroke, (6) shock, (7) brain edema, (8) brain injury, (9) spinal cord injury, (10) brain ischemia, (11) brain failure suffered after heart bypass or transplant surgery, (12) urinary or reproductive tract disorders including incontinence, (13) chem. dependence or addiction, (14) chronic pain, (15) acute or neurol. pain, (16) systemic lupus erythematosus, (17) Hodgkin's disease, (18) Sjogren disease, (19) epilepsy, and (20) rejection of organ transplant or skin grafting (no data). Thus, oxidn. of N,N-diethyl-2-[4-(3-hydroxymethylphenyl)-1-(2-methylpentyl)piperidin-4-yl]pyrimidine-5-carboxamide by tetrapropylammonium perruthenate and N-methylmorpholine N-oxide in CH2Cl2 in the presence of 4.ANG. mol. sieve gave an aldehyde which underwent addn. reaction with methylmagnesium bromide in THF at -70.degree. to give N,N-diethyl-2-[4-[3-(1-hydroxyethyl)phenyl]-1-(2-methylpentyl)piperidin-4-yl]pyrimidine-5-carboxamide.


IT 291754-14-8P 291754-15-9P 291754-17-1P  
291754-19-3P 291754-21-7P 291754-23-9P  
291754-29-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylheteroarylpiperidines as ligands for opioid receptors and drugs)

RN 291754-14-8 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N-diethyl-2-[4-(3-hydroxyphenyl)-1-[2-(phenylmethoxy)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 291754-15-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[1-(2-ethoxypropyl)-4-(3-hydroxyphenyl)-4-piperidinyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

09/ 755,021




RN 291754-17-1 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N-diethyl-2-[4-(3-hydroxyphenyl)-1-[2-(phenylmethoxy)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 291754-19-3 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N-diethyl-2-[4-(3-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 291754-21-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[1-(3-ethoxypropyl)-4-(3-hydroxyphenyl)-4-piperidinyl]-N,N-diethyl- (9CI) (CA INDEX NAME)


09/ 755,021



RN 291754-23-9 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-[1-[2-(diethylamino)ethyl]-4-(3-hydroxyphenyl)-4-piperidinyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 291754-29-5 CAPLUS  
CN 5-Pyrimidinecarboxamide, N-ethyl-2-[4-(3-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2000:451987 CAPLUS  
DOCUMENT NUMBER: 133:114399  
TITLE: ADL-8-2698 (Eli Lilly & Co)  
AUTHOR(S): Galligan, James J.  
CORPORATE SOURCE: Michigan State University, East Lansing, MI, 48824, USA  
SOURCE: Current Opinion in Central & Peripheral Nervous System Investigational Drugs (2000), 2(3), 378-383

CODEN: COCDFA; ISSN: 1464-844X

PUBLISHER:

PharmaPress Ltd.

DOCUMENT TYPE:

Journal; General Review

LANGUAGE:

English

AB A review with 28 refs. ADL-8-2698 (LY-246736) is a potent, peripherally active,  $\mu$ -opioid receptor antagonist being developed by Adolor and Shire (formerly Roberts Pharmaceuticals), under license from Eli Lilly, as a potential treatment for constipation, post-surgical ileus and irritable bowel syndrome. It is in phase III trials for constipation and phase II trials for post-surgical ileus. Phase II/III trials were initiated for narcotic-induced constipation in Nov. 1999. Shire expects to file an NDA for ADL-8-2698 in 2002. A series of phase I and II studies involving more than 130 volunteers, acute pain patients and chronic opioid therapy patients were carried out by Adolor and had been completed and analyzed by Nov. 1999. The results showed that the compd. reversed narcotic-induced constipation and did not reverse narcotic-induced analgesia or ppt. opioid withdrawal. ADL-8-2698 was safe and well tolerated with no significant side effects. Phase II trials for post-surgical ileus were initiated by Nov. 1999. ADL-8-2698 does not readily cross the blood-brain barrier. In a mouse model of GI transit ADL-8-2698 antagonized morphine-induced inhibition of GI transit with an ED50 value of 0.46 mg/kg po, with a max. effect at 6 h. ADL-01-0160 (100 mg/kg), a member of the same series, also produced maximal antagonism at 6 h and inhibited transit up to 8 h. With ADL-01-0161 (100 mg/kg), maximal inhibition of transit occurred at 8 h and transit was still inhibited at 24 h, with an ED50 value of 16 mg/kg. No abstinence-induced jumping in mice pretreated with 100 mg/kg morphine, indicating peripheral selectivity. In June 1998, Roberts out-licensed ADL-8-2698 to Adolor in order to accelerate the compd.'s development.

IT 156053-89-3, LY-246736 170098-38-1


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

( $\mu$ -opioid receptor antagonist ADL-8-2698 for treatment of gastrointestinal disorders)

RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 170098-38-1 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, dihydrate (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



⊙ 2 H<sub>2</sub>O

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2000:104848 CAPLUS  
 DOCUMENT NUMBER: 132:265068  
 TITLE: Synthesis of N-Substituted 4-(4-Hydroxyphenyl)piperidines, 4-(4-Hydroxybenzyl)piperidines, and (.+-.)-3-(4-Hydroxyphenyl)pyrrolidines: Selective Antagonists at the 1A/2B NMDA Receptor Subtype  
 AUTHOR(S): Guzikowski, Anthony P.; Tamiz, Amir P.; Acosta-Burrueal, Manuel; Hong-Bae, Soo; Cai, Sui Xiong; Hawkinson, Jon E.; Keana, John F. W.; Kesten, Suzanne R.; Shipp, Christina T.; Tran, Minhtam; Whittemore, Edward R.; Woodward, Richard M.; Wright, Jon L.; Zhou, Zhang-Lin  
 CORPORATE SOURCE: CoCensys Inc., Irvine, CA, 92618, USA  
 SOURCE: Journal of Medicinal Chemistry (2000), 43(5), 984-994  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 132:265068  
 GI



AB Antagonists at the 1A/2B subtype of the NMDA receptor (NR1A/2B) are typically small mols. that consist of a 4-benzyl- or a 4-phenylpiperidine with an .omega.-phenylalkyl substituent on the heterocyclic nitrogen. Many of these antagonists, for example ifenprodil, incorporate a 4-hydroxy substituent on the .omega.-Ph group. In this study, the position of this 4-hydroxy substituent was transferred from the .omega.-Ph group to the benzyl or Ph group located on the 4-position of the piperidine ring. Analogs incorporating pyrrolidine in lieu of piperidine were also prepd. Elec. recordings using cloned receptors expressed in *Xenopus* oocytes show that high-potency antagonists at the NR1A/2B subtype are obtained employing N-(.omega.-phenylalkyl)-substituted 4-(4-hydroxyphenyl)piperidine, 4-(4-hydroxybenzyl)piperidine, and

(.+-.)-3-(4-hydroxyphenyl)pyrrolidine as exemplified by I [X = bond, X1 = CH2, n = 4] (IC50 = 0.022 .mu.M), I [X = X1 = CH2, n = 3] (IC50 = 0.059 .mu.M), and I [X = X1 = bond, n = 5] (IC50 = 0.017 .mu.M), resp. These high-potency antagonists are >1000 times more potent at the NR1A/2B subtype than at either the NR1A/2A or NR1A/2C subtypes. The binding affinities of I [X = bond, X1 = CH2, n = 4] at .alpha.1-adrenergic receptors ([3H]prazosin, IC50 = 0.54 .mu.M) and dopamine D2 receptors ([3H]raclopride, IC50 = 1.2 .mu.M) are reduced by incorporating a hydroxy group onto the 4-position of the piperidine ring and the .beta.-carbon of the N-alkyl spacer (IC50 NR1A/2B, 0.026; .alpha.1, 14; D2, 105 .mu.M). The high-potency phenolic antagonist I [X = bond, X1 = CH2, n = 4] and its low-potency O-methylated analog are both potent anticonvulsants in a mouse maximal electroshock-induced seizure (MES) study (ED50 (iv) = 0.23 and 0.56 mg/kg, resp.). These data indicate that such compds. penetrate the blood-brain barrier but their MES activity may not be related to NMDA receptor antagonism.

IT 263139-36-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of N-Substituted hydroxyphenylpiperidines, hydroxybenzylpiperidines, and hydroxyphenylpyrrolidines as selective antagonists at the 1A/2B NMDA receptor subtype)


RN 263139-36-2 CAPLUS

CN Phenol, 4-[1-[2-(phenylmethoxy)ethyl]-4-piperidinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 263139-35-1


CMF C20 H25 N O2



CM 2

CRN 77-92-9

CMF C6 H8 O7



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:594935 CAPLUS

DOCUMENT NUMBER: 131:228652

TITLE: Preparation of substituted piperidines for pharmaceutical use as opioid antagonists

INVENTOR(S): Carroll, Frank Ivy

09/ 755,021

PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 171 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945925	A1	19990916	WO 1999-US5131	19990309
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2324418	AA	19990916	CA 1999-2324418	19990309
AU 9930738	A1	19990927	AU 1999-30738	19990309
AU 756983	B2	20030130		
EP 1061919	A1	20001227	EP 1999-912345	19990309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002506032	T2	20020226	JP 2000-535340	19990309
US 2002165396	A1	20021107	US 2002-100097	20020319
US 6552032	B2	20030422		
US 2002169324	A1	20021114	US 2002-100096	20020319
US 6593348	B2	20030715		
US 2002193602	A1	20021219	US 2002-99948	20020319
US 6531481	B2	20030311		
US 2003158415	A1	20030821	US 2002-266774	20021009
PRIORITY APPLN. INFO.:				
			US 1998-77402P	P 19980310
			US 1998-107902P	P 19981110
			WO 1999-US5131	W 19990309
			US 2000-623872	A3 20001127
			US 2002-99948	A1 20020319
OTHER SOURCE(S): MARPAT 131:228652				
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Piperidine contg. heterocyclic compds. I [R1, R2 = H, alkyl, aryl, arylalkyl; R3 = alkyl, cycloalkyl, aryl, arylalkyl, etc.], II [R1 = alkyl, arylalkyl; R3, R4, R5, R6 = H, OH, NH2, CN, CF3, CN, NO2, alkyl, alkyloxy, halogen, amino, etc.; R7 = H, alkyl], and III [R1 = alkyl, arylalkyl; R2 = H, NH2, :O, alkyl, arylalkyl, amino, etc.] were prepd. for use as opioid antagonists to treat a variety of disease states which involve the opioid receptors. Thus, the hydrochloride salt of piperidine IV [R3 = (CH2)2C6H4-4-OH], i.e. RTI 5989-29, was prepd. starting from (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine, N-(tert-butoxycarbonyl)-L-valine, and 3-(4-hydroxyphenyl)propanoic acid. The prepd. heterocyclic compds. contg. a piperidine subunit were tested for .kappa.-, .mu.-, and .delta.-opioid receptor binding activity.

IT 220124-25-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT

09/ 755,021


(Reactant or reagent); USES (Uses)

(prepn. of heterocyclic compds. contg. a piperidine subunit for  
pharmaceutical use as opioid antagonists)

RN 220124-25-4 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-  
dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220122-69-0P, RTI 5989-29 220122-70-3P  
220122-71-4P 220122-73-6P 220122-74-7P  
220122-75-8P 220122-76-9P 220122-77-0P  
220122-80-5P 220122-81-6P 220122-82-7P  
220122-83-8P 220122-84-9P 220122-85-0P  
220122-86-1P 220122-87-2P 220122-88-3P  
220122-90-7P 220122-91-8P 220122-92-9P  
220122-93-0P 220122-94-1P 220122-95-2P  
220122-97-4P 220122-99-6P 220123-00-2P  
220123-02-4P 220123-03-5P 220123-04-6P  
220123-05-7P 220123-06-8P 220123-07-9P  
220123-08-0P 220123-09-1P 220123-10-4P  
220123-11-5P 220123-12-6P 220123-13-7P  
220123-14-8P 220123-15-9P 220123-16-0P  
220123-17-1P 220123-18-2P 220123-20-6P  
220123-21-7P 220123-22-8P 220123-23-9P  
220123-24-0P 220123-25-1P 220123-26-2P  
220123-27-3P 220123-28-4P 220123-29-5P  
220123-30-8P 220123-31-9P 220123-32-0P  
220123-33-1P 220123-34-2P 220123-35-3P  
220123-36-4P 220123-37-5P 220123-38-6P  
220123-39-7P 220123-40-0P 220123-41-1P  
220123-42-2P 220123-43-3P 220123-45-5P  
220123-47-7P 220123-49-9P 220123-50-2P  
220123-52-4P 220123-53-5P 220123-54-6P  
220123-55-7P 220123-56-8P 220123-60-4P  
220123-61-5P 220123-62-6P 220123-63-7P  
220123-64-8P 220123-65-9P 220123-71-7P  
220123-72-8P 220123-73-9P 220123-74-0P  
220123-80-8P 220123-81-9P 220123-86-4P  
220123-87-5P 220123-88-6P 220123-89-7P  
220123-90-0P 220123-91-1P 220123-97-7P  
220123-98-8P 220123-99-9P 220124-00-5P  
220124-01-6P 220124-02-7P 220124-03-8P  
220124-04-9P 220124-05-0P 220124-06-1P  
220124-07-2P 220124-08-3P 220124-09-4P  
220124-10-7P 220124-11-8P 220124-12-9P  
220124-13-0P 220124-14-1P 220124-15-2P  
220124-16-3P 220124-17-4P 220124-18-5P  
220124-19-6P 220124-20-9P 220124-21-0P  
220124-22-1P 220124-23-2P 220124-26-5P



220124-27-6P 220124-28-7P 220124-29-8P  
 220124-30-1P 220124-31-2P 220124-32-3P  
 220124-33-4P 220124-34-5P 220124-35-6P  
 220124-36-7P 220124-37-8P 220124-38-9P  
 220124-39-0P 220124-40-3P 220124-41-4P  
 220124-45-8P 220124-46-9P 220124-47-0P  
 220124-49-2P 220124-50-5P 220124-51-6P  
 220124-52-7P 220124-53-8P 220124-54-9P  
 220124-55-0P 220124-56-1P 220124-57-2P  
 220124-58-3P 220124-59-4P 220124-60-7P  
 220124-61-8P 220124-62-9P 220124-64-1P  
 220124-65-2P 220124-66-3P 220124-67-4P  
 220124-68-5P 220124-69-6P 220124-70-9P  
 220124-71-0P 220124-72-1P 220124-73-2P  
 220124-74-3P 220124-76-5P 220124-77-6P  
 220124-78-7P 220124-80-1P 220124-81-2P  
 220124-82-3P 220124-83-4P 220124-84-5P  
 220124-85-6P 220124-86-7P 220124-87-8P  
 220124-88-9P 220124-89-0P 220124-90-3P  
 220124-91-4P 220124-92-5P 220124-93-6P  
 220124-94-7P 220124-95-8P 220124-96-9P  
 220124-97-0P 220124-98-1P 220124-99-2P  
 220125-00-8P 220125-01-9P 220125-02-0P  
 220125-03-1P 220125-04-2P 220125-05-3P  
 220125-16-6P 220125-17-7P 220125-19-9P  
 220125-20-2P 220125-22-4P 220125-24-6P  
 220125-25-7P 220125-26-8P 220125-27-9P  
 220125-28-0P 220125-29-1P 220125-30-4P  
 220125-32-6P 220125-33-7P 220125-34-8P  
 220125-35-9P 220125-36-0P 220125-37-1P  
 220125-38-2P 220125-39-3P 220125-40-6P  
 220125-42-8P 220125-43-9P 220125-44-0P  
 220125-45-1P 220125-46-2P 220125-47-3P  
 220125-48-4P 220125-49-5P 220125-50-8P  
 220125-52-0P 220125-53-1P 220125-54-2P  
 220125-55-3P 220125-56-4P 220125-57-5P  
 220125-58-6P 220125-59-7P 220125-60-0P  
 220125-61-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of heterocyclic compds. contg. a piperidine subunit for pharmaceutical use as opioid antagonists)

RN 220122-69-0 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

09/ 755,021




● HCl

RN 220122-70-3 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-71-4 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-73-6 CAPLUS

CN Benzenepropanamide, 3-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-74-7 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-75-8 CAPLUS

CN Benzeneacetamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-76-9 CAPLUS

CN 2-Propenamide, 3-(4-hydroxyphenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


09/ 755,021



RN 220122-77-0 CAPLUS

CN Benzenepropanamide, 4-fluoro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-80-5 CAPLUS

CN Benzenepropanamide, 3,4-dihydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-81-6 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-82-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-83-8 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-84-9 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-85-0 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-86-1 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-87-2 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-88-3 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-90-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-cyclohexyl-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-91-8 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-92-9 CAPLUS

CN Benzamide, 4-((1,1-dimethylethyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-93-0 CAPLUS

CN Benzamide, 2-benzoyl-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-94-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220122-95-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-97-4 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-99-6 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-00-2 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-.beta.-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-02-4 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-03-5 CAPLUS

CN Benzenepropanamide, 3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-04-6 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-05-7 CAPLUS

CN Benzenepropanamide, 3,4-dihydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-06-8 CAPLUS

CN Acetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-07-9 CAPLUS

CN Propanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-08-0 CAPLUS

CN Propanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-09-1 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-10-4 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-11-5 CAPLUS

CN Butanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-12-6 CAPLUS

CN Pentanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-13-7 CAPLUS

CN Cyclopentaneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-14-8 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-15-9 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-16-0 CAPLUS

CN Butanamide, 2-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-17-1 CAPLUS

CN Butanamide, 2-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-18-2 CAPLUS

CN Butanamide, 3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-20-6 CAPLUS

CN Benzeneacetamide, .alpha.-(hydroxymethyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-21-7 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 220123-22-8 CAPLUS


CN 2-Propenamide, 3-(2-hydroxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




09/ 755,021



RN 220123-23-9 CAPLUS

CN 2-Propenamide, 3-(3-hydroxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220123-24-0 CAPLUS

CN 2-Propenamide, 3-(4-hydroxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220123-25-1 CAPLUS

CN Benzeneacetamide, 4-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-26-2 CAPLUS

CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220123-27-3 CAPLUS

CN 2-Propenamide, 3-[1,1'-biphenyl]-4-yl-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220123-28-4 CAPLUS

CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220123-29-5 CAPLUS

CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 220123-30-8 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-31-9 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-32-0 CAPLUS

CN Benzeneacetamide, 2,6-dichloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-33-1 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2,5-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-34-2 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2,4-dinitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220123-35-3 CAPLUS

CN Benzeneacetamide, 4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-36-4 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-37-5 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-38-6 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-39-7 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-40-0 CAPLUS

CN Benzeneacetamide, 2-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-41-1 CAPLUS

CN Benzeneacetamide, 4-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-42-2 CAPLUS

09/ 755,021

CN Benzeneacetamide, 3-chloro-4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-43-3 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-45-5 CAPLUS

CN Benzeneacetamide, 2-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-47-7 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-49-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinylethyl]-2-(pentylthio)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-50-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinylethyl]-2-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-52-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinylethyl]-2-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220123-53-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-54-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-55-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-56-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-60-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-61-5 CAPLUS

CN Benzamide, 4-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-62-6 CAPLUS

CN 1-Piperidinepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-63-7 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-64-8 CAPLUS

CN Butanamide, 4-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-65-9 CAPLUS

CN Benzamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-71-7 CAPLUS

CN Benzamide, 4-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-72-8 CAPLUS

CN Benzamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 755,021




RN 220123-73-9 CAPLUS

CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N,2-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220123-74-0 CAPLUS

CN 2-Propenamide, 3-(2,4-dichlorophenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220123-80-8 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N,2,4,6-tetramethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-81-9 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-86-4 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-87-5 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-88-6 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-.beta.-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-89-7 CAPLUS

CN Benzenepropanamide, 3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-90-0 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-91-1 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-97-7 CAPLUS

CN 2-Propenamide, 3-(2-chlorophenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220123-98-8 CAPLUS

CN Benzamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220123-99-9 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-phenoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-00-5 CAPLUS

CN Benzamide, 4-(dimethylamino)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-01-6 CAPLUS

CN Benzamide, 4-(dodecyloxy)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-02-7 CAPLUS

CN Benzamide, 4-butoxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-03-8 CAPLUS

CN Benzamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-04-9 CAPLUS

CN Benzamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-05-0 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-06-1 CAPLUS

CN 2-Propenamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-07-2 CAPLUS

CN 2-Propenamide, 3-(2-hydroxyphenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

09/ 755,021




RN 220124-08-3 CAPLUS

CN 2-Propenamide, 3-(3-hydroxyphenyl)-N-[(1S)-1-[[3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-09-4 CAPLUS

CN 2-Propenamide, 3-(2,4-dimethoxyphenyl)-N-[(1S)-1-[[3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-10-7 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[(1S)-1-[[3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-11-8 CAPLUS

CN Benzeneacetamide, 3-chloro-4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 220124-12-9 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-13-0 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-14-1 CAPLUS

CN Benzeneacetamide, 2,6-dichloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-15-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylpropyl]-2,5-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-16-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylpropyl]-2,4-dinitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220124-17-4 CAPLUS

CN Benzeneacetamide, 2-hydroxy-N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-18-5 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-19-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-20-9 CAPLUS


CN 2-Propenamide, N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-21-0 CAPLUS  
 CN 2-Propenamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-(4-methylphenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.



RN 220124-22-1 CAPLUS  
 CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-23-2 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-.beta.-phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220124-26-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-27-6 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-28-7 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-29-8 CAPLUS

CN 2-Propenamide, 3-(2,4-dichlorophenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-30-1 CAPLUS

CN 2-Propenamide, 3-(4-hydroxyphenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-31-2 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-32-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-33-4 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-34-5 CAPLUS

CN 2-Propenamide, 3-(2-chlorophenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-35-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-

09/ 755,021

dimethyl-1-piperidinyl)methyl]-2-methylpropyl]-2-(pentylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-36-7 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-37-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-38-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-39-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-(methylthio)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-40-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-41-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-45-8 CAPLUS

CN Benzeneacetamide, 4-(dimethylamino)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylpropyl]-2-methylpropyl]-2-methylpropylbenzeneacetamide (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-46-9 CAPLUS

CN 1-Piperidinepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylpropyl]-2-methylpropyl]-2-methylpropyl-4-(dimethylaminophenyl)propanamide (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-47-0 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylpropyl]-2-methylpropyl]-2-methylpropyl-4-(dimethylaminophenyl)propanamide (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-49-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-50-5 CAPLUS

CN Acetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-51-6 CAPLUS

CN Propanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-52-7 CAPLUS

CN Propanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-

09/ 755,021

piperidinyl)methyl]-2-methylpropyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-53-8 CAPLUS

CN Cyclopentanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]-1-phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-54-9 CAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]-1-phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-55-0 CAPLUS

CN Butanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]-3-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220124-56-1 CAPLUS

CN Pentanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-57-2 CAPLUS

CN Cyclopentaneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-58-3 CAPLUS

CN Cyclopentanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-59-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-phenyl- (9CI) (CA INDEX NAME)

09/ 755,021

NAME)


Absolute stereochemistry.



RN 220124-60-7 CAPLUS

CN Butanamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-61-8 CAPLUS

CN Butanamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-62-9 CAPLUS

CN Butanamide, 3-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220124-64-1 CAPLUS

CN Benzeneacetamide, .alpha.-(hydroxymethyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 220124-65-2 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-66-3 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-67-4 CAPLUS

CN Benzenepropanamide, N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-68-5 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-69-6 CAPLUS

CN Benzenepropanamide, 3,4-dihydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-70-9 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-71-0 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1R)-1-[[3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3,5-dinitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-72-1 CAPLUS

CN Benzenepropanamide, 2,3,4,5,6-pentafluoro-N-[(1R)-1-[[3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-73-2 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,2-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)


09/ 755,021

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-74-3 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-76-5 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-(3-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-77-6 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-78-7 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-80-1 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-81-2 CAPLUS

CN 2-Propenamide, 3-[2-(hexyloxy)phenyl]-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220124-82-3 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-[2-(phenylmethoxy)phenyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-83-4 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-84-5 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021




RN 220124-85-6 CAPLUS  
CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-86-7 CAPLUS  
CN Benzamide, 4-butoxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-87-8 CAPLUS  
CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-88-9 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-89-0 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-90-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-91-4 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-92-5 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-93-6 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-94-7 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-95-8 CAPLUS

CN Benzeneacetamide, 2-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-96-9 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021




RN 220124-97-0 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-98-1 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-99-2 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-00-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-01-9 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-02-0 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-03-1 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-04-2 CAPLUS

CN Benzenepropanamide, 3-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-05-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-16-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-17-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-19-9 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,2,5-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021




RN 220125-20-2 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220125-22-4 CAPLUS  
CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-.beta.-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-24-6 CAPLUS  
CN Benzeneacetamide, 3-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-25-7 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N,2-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220125-26-8 CAPLUS

CN 2-Propenamide, 3-(2-chlorophenyl)-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220125-27-9 CAPLUS

CN 2-Propenamide, 3-(3-fluorophenyl)-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

09/ 755,021




RN 220125-28-0 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-3-(3-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 220125-29-1 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-3-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220125-30-4 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220125-32-6 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-33-7 CAPLUS

CN Benzamide, 2-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-34-8 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-35-9 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-36-0 CAPLUS

CN Benzeneacetamide, 2-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-37-1 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-38-2 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-.beta.-phenyl-. (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-39-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-.alpha.-(phenylmethylene)-. (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220125-40-6 CAPLUS

CN Benzanide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-4-methoxy-N-methyl-. (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-42-8 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-3-phenoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-43-9 CAPLUS

CN Benzamide, 4-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-44-0 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-45-1 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-46-2 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-47-3 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220125-48-4 CAPLUS

CN Benzenacetamide, 4-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-49-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-50-8 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-52-0 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-53-1 CAPLUS

CN Benzamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-54-2 CAPLUS

CN Benzamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-55-3 CAPLUS

CN Benzamide, 3-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-56-4 CAPLUS

CN Benzamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-57-5 CAPLUS

CN Benzamide, 3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-58-6 CAPLUS

CN Benzamide, 4-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-59-7 CAPLUS

CN Benzamide, 4-(dodecyloxy)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-60-0 CAPLUS

CN Benzamide, 4-butoxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-61-1 CAPLUS

CN Benzamide, 4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220125-69-9P 244048-35-9P 244048-69-9P  
244048-70-2P 244048-71-3P 244048-72-4P  
244048-73-5P 244048-74-6P 244048-75-7P  
244048-76-8P 244048-77-9P 244048-78-0P  
244048-79-1P 244048-80-4P 244048-81-5P  
244048-82-6P 244048-83-7P 244048-84-8P  
244048-85-9P 244048-86-0P 244048-87-1P  
244048-88-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of heterocyclic compds. contg. a piperidine subunit for pharmaceutical use as opioid antagonists)

RN 220125-69-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 244048-35-9 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S,2S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244048-69-9 CAPLUS

CN Benzanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244048-70-2 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-.beta.-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 244048-71-3 CAPLUS

CN 1-Butanaminium, 2-hydroxy-4-[[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-N,N,N-trimethyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244048-72-4 CAPLUS

CN 2-Pyridineacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 244048-73-5 CAPLUS

CN 3-Pyridineacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 755,021




● HCl

RN 244048-74-6 CAPLUS

CN 4-Pyridineacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 244048-75-7 CAPLUS

CN Benzamide, 3-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244048-76-8 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-.beta.-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 244048-77-9 CAPLUS

CN 2-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 244048-78-0 CAPLUS

CN 3-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 244048-79-1 CAPLUS

CN 4-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 755,021




● HCl

RN 244048-80-4 CAPLUS

CN Butanamide, 4-(dimethylamino)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244048-81-5 CAPLUS

CN 1-Butanaminium, 2-hydroxy-4-[[[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]amino]-N,N,N-trimethyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244048-82-6 CAPLUS

CN 2-Propenamide, 3-(2,4-dimethoxyphenyl)-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 244048-83-7 CAPLUS

CN 2-Propenamide, 3-[1,1'-biphenyl]-4-yl-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 244048-84-8 CAPLUS

CN 2-Propenamide, 3-(2-hydroxyphenyl)-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 244048-85-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 244048-86-0 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,.beta.-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 244048-87-1 CAPLUS

CN 2-Propenamide, 3-[1,1'-biphenyl]-4-yl-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 244048-88-2 CAPLUS


CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N,.beta.-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1998:749847 CAPLUS  
 DOCUMENT NUMBER: 130:139233  
 TITLE: Identification of an Opioid .kappa. Receptor  
 Subtype-Selective N-Substituent for  
 (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)piperidine  
 AUTHOR(S): Thomas, James B.; Fall, Michael J.; Cooper, Julie B.;  
 Rothman, Richard B.; Mascarella, S. Wayne; Xu, Heng;  
 Partilla, John S.; Dersch, Christina M.; McCullough,  
 Karen B.; Cantrell, Buddy E.; Zimmerman, Dennis M.;  
 Carroll, F. Ivy  
 CORPORATE SOURCE: Chemistry and Life Sciences Research Triangle  
 Institute, Research Triangle Park, NC, 27709, USA  
 SOURCE: Journal of Medicinal Chemistry (1998), 41(26),  
 5188-5197  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



I

AB A three-component library of compds. was prepd. in parallel using multiple simultaneous soln.-phase synthetic methodol. The compds. were biased toward opioid receptor antagonist activity by incorporating (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine (a potent, nonselective opioid pure antagonist) as one of the monomers. The other two monomers were N-substituted or unsubstituted Boc-protected amino acids and a range

of substituted aryl carboxylic acids and were selected to add chem. diversity. Screening of these compds. in competitive binding expts. with the .kappa. opioid receptor selective ligand [3H]U69,593 led to the discovery of a novel .kappa. opioid receptor selective ligand, RTI-5989-29 (I). Addnl. structure-activity relationship studies suggested that I possesses lipophilic and hydrogen-bonding sites that are important to its opioid receptor potency and selectivity. These sites appear to exist predominantly within the .kappa. receptor since the selectivity arises from a 530-fold loss of affinity of I for the .mu. receptor and an 18-fold increase in affinity for the .kappa. receptor relative to the .mu.-selective ligand, (+)-N-[trans-4-phenyl-2-butenyl]-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. The degree of selectivity obsd. in the radioligand binding expts. was not obsd. in the functional assay. According to its ability to inhibit agonist stimulated binding of [35S]GTP.gamma.S at all three opioid receptors, I behaves as a .mu./kappa. opioid receptor pure antagonist with negligible affinity for the .delta. receptor.

IT 220122-69-0P 220122-70-3P 220122-71-4P  
 220122-73-6P 220122-74-7P 220122-75-8P  
 220122-76-9P 220122-77-0P 220122-80-5P  
 220122-81-6P 220122-82-7P 220122-83-8P  
 220122-84-9P 220122-85-0P 220122-86-1P  
 220122-87-2P 220122-88-3P 220122-89-4P  
 220122-90-7P 220122-91-8P 220122-92-9P  
 220122-93-0P 220122-94-1P 220122-95-2P  
 220122-97-4P 220122-99-6P 220123-00-2P  
 220123-01-3P 220123-02-4P 220123-03-5P  
 220123-04-6P 220123-05-7P 220123-06-8P  
 220123-07-9P 220123-08-0P 220123-09-1P  
 220123-10-4P 220123-11-5P 220123-12-6P  
 220123-13-7P 220123-14-8P 220123-15-9P  
 220123-16-0P 220123-17-1P 220123-18-2P  
 220123-19-3P 220123-20-6P 220123-21-7P  
 220123-22-8P 220123-23-9P 220123-24-0P  
 220123-25-1P 220123-26-2P 220123-27-3P  
 220123-28-4P 220123-29-5P 220123-30-8P  
 220123-31-9P 220123-32-0P 220123-33-1P  
 220123-34-2P 220123-35-3P 220123-36-4P  
 220123-37-5P 220123-38-6P 220123-39-7P  
 220123-40-0P 220123-41-1P 220123-42-2P  
 220123-43-3P 220123-45-5P 220123-47-7P  
 220123-49-9P 220123-50-2P 220123-52-4P  
 220123-53-5P 220123-54-6P 220123-55-7P  
 220123-56-8P 220123-57-9P 220123-58-0P  
 220123-59-1P 220123-60-4P 220123-61-5P  
 220123-62-6P 220123-63-7P 220123-64-8P  
 220123-65-9P 220123-66-0P 220123-67-1P  
 220123-69-3P 220123-70-6P 220123-71-7P  
 220123-72-8P 220123-73-9P 220123-74-0P  
 220123-75-1P 220123-76-2P 220123-77-3P  
 220123-78-4P 220123-79-5P 220123-80-8P  
 220123-81-9P 220123-82-0P 220123-83-1P  
 220123-84-2P 220123-85-3P 220123-86-4P  
 220123-87-5P 220123-88-6P 220123-89-7P  
 220123-90-0P 220123-91-1P 220123-92-2P  
 220123-93-3P 220123-94-4P 220123-95-5P  
 220123-96-6P 220123-97-7P 220123-98-8P  
 220123-99-9P 220124-00-5P 220124-01-6P  
 220124-02-7P 220124-03-8P 220124-04-9P  
 220124-05-0P 220124-06-1P 220124-07-2P  
 220124-08-3P 220124-09-4P 220124-10-7P  
 220124-11-8P 220124-12-9P 220124-13-0P  
 220124-14-1P 220124-15-2P 220124-16-3P

220124-17-4P 220124-18-5P 220124-19-6P  
 220124-20-9P 220124-21-0P 220124-22-1P  
 220124-23-2P 220124-24-3P 220124-25-4P  
 220124-26-5P 220124-27-6P 220124-28-7P  
 220124-29-8P 220124-30-1P 220124-31-2P  
 220124-32-3P 220124-33-4P 220124-34-5P  
 220124-35-6P 220124-36-7P 220124-37-8P  
 220124-38-9P 220124-39-0P 220124-40-3P  
 220124-41-4P 220124-42-5P 220124-43-6P  
 220124-44-7P 220124-45-8P 220124-46-9P  
 220124-47-0P 220124-48-1P 220124-49-2P  
 220124-50-5P 220124-51-6P 220124-52-7P  
 220124-53-8P 220124-54-9P 220124-55-0P  
 220124-56-1P 220124-57-2P 220124-58-3P  
 220124-59-4P 220124-60-7P 220124-61-8P  
 220124-62-9P 220124-63-0P 220124-64-1P  
 220124-65-2P 220124-66-3P 220124-67-4P  
 220124-68-5P 220124-69-6P 220124-70-9P  
 220124-71-0P 220124-72-1P 220124-73-2P  
 220124-74-3P 220124-75-4P 220124-76-5P  
 220124-77-6P 220124-78-7P 220124-79-8P  
 220124-80-1P 220124-81-2P 220124-82-3P  
 220124-83-4P 220124-84-5P 220124-85-6P  
 220124-86-7P 220124-87-8P 220124-88-9P  
 220124-89-0P 220124-90-3P 220124-91-4P  
 220124-92-5P 220124-93-6P 220124-94-7P  
 220124-95-8P 220124-96-9P 220124-97-0P  
 220124-98-1P 220124-99-2P 220125-00-8P  
 220125-01-9P 220125-02-0P 220125-03-1P  
 220125-04-2P 220125-05-3P 220125-06-4P  
 220125-07-5P 220125-08-6P 220125-09-7P  
 220125-10-0P 220125-11-1P 220125-12-2P  
 220125-13-3P 220125-14-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of an opioid antagonist combinatorial library of acylaminoethylpiperidinylphenols)

RN 220122-69-0 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, monohydrochloride (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




HCl

RN 220122-70-3 CAPLUS

09/ 755,021

CN Benzenepropanamide, 4-hydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-71-4 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-73-6 CAPLUS

CN Benzenepropanamide, 3-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-74-7 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 220122-75-8 CAPLUS

CN Benzeneacetamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-76-9 CAPLUS

CN 2-Propenamide, 3-(4-hydroxyphenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 220122-77-0 CAPLUS

CN Benzenepropanamide, 4-fluoro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-80-5 CAPLUS

CN Benzenepropanamide, 3,4-dihydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-81-6 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-82-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-83-8 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-84-9 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-85-0 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-86-1 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-87-2 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-88-3 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-3-methylbutyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-89-4 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-90-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-cyclohexyl-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-91-8 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-92-9 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-93-0 CAPLUS

CN Benzamide, 2-benzoyl-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-94-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220122-95-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220122-97-4 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220122-99-6 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-00-2 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-.beta.-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-01-3 CAPLUS

CN Benzenebutanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-02-4 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






09/ 755,021

RN 220123-03-5 CAPLUS

CN Benzenepropanamide, 3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-04-6 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-05-7 CAPLUS

CN Benzenepropanamide, 3,4-dihydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-06-8 CAPLUS

CN Acetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-07-9 CAPLUS

CN Propanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-08-0 CAPLUS

CN Propanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-09-1 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-10-4 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-1-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-11-5 CAPLUS

CN Butanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-12-6 CAPLUS

CN Pentanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-13-7 CAPLUS

CN Cyclopentaneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-14-8 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-15-9 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-16-0 CAPLUS

CN Butanamide, 2-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-17-1 CAPLUS

CN Butanamide, 2-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-18-2 CAPLUS

CN Butanamide, 3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-19-3 CAPLUS

CN Butanamide, 4-(dimethylamino)-3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-20-6 CAPLUS

CN Benzeneacetamide, .alpha.-(hydroxymethyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-21-7 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


09/ 755,021



RN 220123-22-8 CAPLUS

CN 2-Propenamide, 3-(2-hydroxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220123-23-9 CAPLUS

CN 2-Propenamide, 3-(3-hydroxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220123-24-0 CAPLUS

CN 2-Propenamide, 3-(4-hydroxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220123-25-1 CAPLUS

CN Benzeneacetamide, 4-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-26-2 CAPLUS

CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 220123-27-3 CAPLUS


CN 2-Propenamide, 3-[1,1'-biphenyl]-4-yl-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




09/ 755,021



RN 220123-28-4 CAPLUS

CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220123-29-5 CAPLUS

CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 220123-30-8 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-31-9 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-32-0 CAPLUS

CN Benzeneacetamide, 2,6-dichloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-33-1 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2,5-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-34-2 CAPLUS

09/ 755,021

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2,4-dinitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-35-3 CAPLUS

CN Benzeneacetamide, 4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-36-4 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-37-5 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-38-6 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-39-7 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-40-0 CAPLUS

CN Benzeneacetamide, 2-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-41-1 CAPLUS

CN Benzeneacetamide, 4-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-

09/ 755,021

piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-42-2 CAPLUS

CN Benzeneacetamide, 3-chloro-4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-43-3 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-45-5 CAPLUS

CN Benzeneacetamide, 2-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-47-7 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-49-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-(pentylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-50-2 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-52-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-53-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-54-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-55-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-56-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-57-9 CAPLUS

CN 2-Pyridineacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220123-58-0 CAPLUS

CN 3-Pyridineacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-59-1 CAPLUS

CN 4-Pyridineacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-60-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-61-5 CAPLUS

CN Benzamide, 4-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-

09/ 755,021

dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-62-6 CAPLUS

CN 1-Piperidinepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-63-7 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-64-8 CAPLUS

CN Butanamide, 4-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-65-9 CAPLUS

CN Benzamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-66-0 CAPLUS

CN Benzamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-67-1 CAPLUS

CN Benzamide, 2-(acetylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-69-3 CAPLUS

CN Benzamide, 3-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-70-6 CAPLUS

CN Benzamide, 4-(dimethylamino)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-71-7 CAPLUS

CN Benzamide, 4-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-72-8 CAPLUS

CN Benzamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-73-9 CAPLUS

CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N,2-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220123-74-0 CAPLUS

CN 2-Propenamide, 3-(2,4-dichlorophenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.

09/ 755,021




RN 220123-75-1 CAPLUS  
CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220123-76-2 CAPLUS  
CN 2-Propenamide, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 220123-77-3 CAPLUS  
CN 2-Propenamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-3-phenyl-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 220123-78-4 CAPLUS

CN 2-Propenamide, 3-(3,4-dihydroxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220123-79-5 CAPLUS

CN 2-Propenamide, 3-(2,4-dimethoxyphenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220123-80-8 CAPLUS

CN Benzeneacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N,2,4,6-tetramethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-81-9 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-82-0 CAPLUS

CN Benzeneacetamide, 4-amino-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-83-1 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021




RN 220123-84-2 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220123-85-3 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-86-4 CAPLUS  
CN Benzeneacetamide, 3,4-dichloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-87-5 CAPLUS

CN Benzenacetamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-88-6 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-.beta.-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-89-7 CAPLUS

CN Benzenepropanamide, 3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-90-0 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-91-1 CAPLUS

CN Benzenepropanamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-92-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-2-(pentylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-93-3 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220123-94-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-95-5 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220123-96-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-97-7 CAPLUS

CN 2-Propenamide, 3-(2-chlorophenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 220123-98-8 CAPLUS


CN Benzamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-99-9 CAPLUS  
 CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-00-5 CAPLUS  
 CN Benzamide, 4-(dimethylamino)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-01-6 CAPLUS  
 CN Benzamide, 4-(dodecyloxy)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-02-7 CAPLUS

CN Benzamide, 4-butoxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-03-8 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-04-9 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-05-0 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-06-1 CAPLUS

CN 2-Propenamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 220124-07-2 CAPLUS


CN 2-Propenamide, 3-(2-hydroxyphenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



09/ 755,021




RN 220124-08-3 CAPLUS

CN 2-Propenamide, 3-(3-hydroxyphenyl)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-09-4 CAPLUS

CN 2-Propenamide, 3-(2,4-dimethoxyphenyl)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-10-7 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-11-8 CAPLUS

CN Benzeneacetamide, 3-chloro-4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 220124-12-9 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-13-0 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-14-1 CAPLUS

CN Benzeneacetamide, 2,6-dichloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-15-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2,4-dinitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-16-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2,4-dinitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220124-17-4 CAPLUS

CN Benzeneacetamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-18-5 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-19-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-20-9 CAPLUS


CN 2-Propenamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-21-0 CAPLUS  
 CN 2-Propenamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-(4-methylphenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.



RN 220124-22-1 CAPLUS  
 CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-23-2 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-.beta.-phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-24-3 CAPLUS

CN Benzenebutanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-25-4 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-26-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220124-27-6 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-28-7 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3,5-dinitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-29-8 CAPLUS

CN 2-Propenamide, 3-(2,4-dichlorophenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-30-1 CAPLUS

09/ 755,021

CN 2-Propenamide, 3-(4-hydroxyphenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-31-2 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-32-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-33-4 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Chemical structure of a substituted piperidine derivative. The piperidine ring is substituted with a methyl group (Me) at position 2, a 4-hydroxyphenyl group at position 3, and a 1-phenylpropan-2-yl group at position 4. The stereochemistry at positions 2 and 3 is indicated with 'R' and 'S' labels.

2-Propenamide, 3-(2-chlorophenyl)-N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


CN	3-Pyridinecarboxamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-(pentylthio)- (9CI)	(CA
	INDEX NAME)	

CC(C)SNC(=O)c1cccnc1SCC(C)C

CN 3-Pyridinecarboxamide, 5-bromo-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-37-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-38-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-39-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-40-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-41-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-42-5 CAPLUS

CN 2-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-43-6 CAPLUS

CN 3-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-44-7 CAPLUS

CN 4-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-45-8 CAPLUS

CN Benzeneacetamide, 4-(dimethylamino)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-46-9 CAPLUS

CN 1-Piperidinepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-

09/ 755,021

dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-47-0 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-48-1 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-49-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

Chemical structure of compound 10: A piperidine ring substituted with a 3-hydroxyphenyl group (R), a methyl group (Me), and a 1-((E)-2-phenyl-3-phenyl-2-oxoprop-1-en-1-yl)propan-1-yl group (S). The piperidine ring also has a methyl group (Me) at the 4-position.

Chemical structure of a substituted piperidine derivative. The piperidine ring has a nitrogen atom bonded to a side chain. The side chain consists of a chiral center (S) bonded to an isopropyl group (i-Pr) and an acetamido group (NHAc). The piperidine ring also has two substituents: a methyl group (Me) and a 3-hydroxyphenyl group (OH). The stereochemistry at the ring positions is indicated by dashed and wedged bonds.


Chemical structure of a substituted piperidine derivative. The piperidine ring is substituted with an N-ethyl group (Et-C(=O)-NH-), a 3-methyl-4-(3-hydroxyphenyl) group (Me and R), and a 2-isopropyl-1-(3-oxopropyl) group (i-Pr, S, and NH-C(=O)-Et). The stereochemistry at the 3-position is R and at the 4-position is R.

Chemical structure of compound 10: A piperidine ring substituted with a 3-hydroxyphenyl group (R), a methyl group (R), and a 1-tert-butyl-2-isopropyl-2-oxoethylcarbamoyl group (S).

CN Cyclopentanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1-phenyl- (9CI) (CA INDEX NAME)

09/ 755,021


Absolute stereochemistry.



RN 220124-54-9 CAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1-phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-55-0 CAPLUS

CN Butanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-3-methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-56-1 CAPLUS

CN Pentanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-4-methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220124-57-2 CAPLUS

CN Cyclopentaneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-58-3 CAPLUS

CN Cyclopentanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-59-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-60-7 CAPLUS

CN Butanamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220124-61-8 CAPLUS

CN Butanamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-62-9 CAPLUS

CN Butanamide, 3-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-63-0 CAPLUS

CN Butanamide, 4-(dimethylamino)-3-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-64-1 CAPLUS

CN Benzeneacetamide, .alpha.-(hydroxymethyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI)

09/ 755,021

(CA INDEX NAME)


Absolute stereochemistry.



RN 220124-65-2 CAPLUS

CN Benzenacetamide, 3,4-dichloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-66-3 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-67-4 CAPLUS

CN Benzenepropanamide, N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-68-5 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-69-6 CAPLUS

CN Benzenepropanamide, 3,4-dihydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-70-9 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-71-0 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1R)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3,5-dinitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-72-1 CAPLUS

CN Benzenepropanamide, 2,3,4,5,6-pentafluoro-N-[(1R)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-73-2 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,2-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)


09/ 755,021

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-74-3 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-75-4 CAPLUS  
CN 2-Propenamide, 3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-76-5 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-(3-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220124-77-6 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-78-7 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-79-8 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220124-80-1 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-[3-(phenylmethoxy)phenyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-81-2 CAPLUS

CN 2-Propenamide, 3-[2-(hexyloxy)phenyl]-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-82-3 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-[2-(phenylmethoxy)phenyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220124-83-4 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-84-5 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-85-6 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Chemical structure of a substituted piperidine derivative. The piperidine ring has a methyl group (Me) at position 2 (wedge), a 4-hydroxyphenyl group at position 3 (dashed), and a 4-methoxyphenyl carbonyl group at position 4 (wedge). The nitrogen of the piperidine is connected to a 1-methyl-2-methylthioethyl chain.

Chemical structure of a substituted piperidine derivative. The piperidine ring is substituted with a 4-hydroxyphenyl group (position 2, wedge bond), a methyl group (position 3, wedge bond), and a methyl group (position 4, dashed bond). The nitrogen of the piperidine ring is connected to a 1-methyl-2-methylthioethyl chain. The sulfur atom is connected to a carbonyl group, which is further connected to a 4-(n-butoxy)phenyl group.

Absolute stereochemistry.


09/ 755,021



RN 220123-96-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220123-97-7 CAPLUS

CN 2-Propenamide, 3-(2-chlorophenyl)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220123-98-8 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-phenoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021




RN 220123-99-9 CAPLUS  
CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-00-5 CAPLUS  
CN Benzamide, 4-(dimethylamino)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-01-6 CAPLUS  
CN Benzamide, 4-(dodecyloxy)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-02-7 CAPLUS

CN Benzamide, 4-butoxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-03-8 CAPLUS

CN Benzamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-04-9 CAPLUS

CN Benzamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-05-0 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-06-1 CAPLUS

CN 2-Propenamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-07-2 CAPLUS

CN 2-Propenamide, 3-(2-hydroxyphenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

09/ 755,021




RN 220124-08-3 CAPLUS

CN 2-Propenamide, 3-(3-hydroxyphenyl)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-09-4 CAPLUS

CN 2-Propenamide, 3-(2,4-dimethoxyphenyl)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-10-7 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-11-8 CAPLUS

CN Benzeneacetamide, 3-chloro-4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-12-9 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-13-0 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Benzeneacetamide, 2,6-dichloro-N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

CN Benzeneacetamide, N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2,5-dimethoxy- (9CI) (CA INDEX NAME)

Chemical structure of a substituted piperidine derivative. The piperidine ring has a methyl group (Me) at the 2-position (wedge) and a 4-hydroxyphenyl group at the 3-position (dashed). The nitrogen is substituted with a 1-(4-methoxyphenyl)propan-1-yl group. The chiral center is labeled 'i-Pr'.

CN Benzeneacetamide, N-[(1S)-1-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2,4-dinitro- (9CI) (CA INDEX NAME)




09/ 755,021

RN 220124-17-4 CAPLUS

CN Benzeneacetamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-18-5 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-19-6 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-20-9 CAPLUS

CN 2-Propenamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

09/ 755,021




RN 220124-21-0 CAPLUS  
CN 2-Propenamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-(4-methylphenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-22-1 CAPLUS  
CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-23-2 CAPLUS  
CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-.beta.-phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-24-3 CAPLUS

CN Benzenebutanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-25-4 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-26-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220124-27-6 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-28-7 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3,5-dinitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-29-8 CAPLUS

CN 2-Propenamide, 3-(2,4-dichlorophenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 220124-30-1 CAPLUS

09/ 755,021

CN 2-Propenamide, 3-(4-hydroxyphenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-31-2 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-32-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-33-4 CAPLUS

CN Benzamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-34-5 CAPLUS

CN 2-Propenamide, 3-(2-chlorophenyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-35-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-(pentylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-36-7 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-37-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylthio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-38-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-chloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylthio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-39-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylthio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-40-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-41-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-42-5 CAPLUS

CN 2-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220124-43-6 CAPLUS

CN 3-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-44-7 CAPLUS

CN 4-Pyridineacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-45-8 CAPLUS

CN Benzeneacetamide, 4-(dimethylamino)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-46-9 CAPLUS

CN 1-Piperidinepropanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-

09/ 755,021

dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-47-0 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-48-1 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-49-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl]-2-methylpropyl]-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


09/ 755,021



RN 220124-50-5 CAPLUS

CN Acetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-51-6 CAPLUS

CN Propanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-52-7 CAPLUS

CN Propanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2,2-dimethyl-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-53-8 CAPLUS

CN Cyclopentanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1-phenyl]- (9CI) (CA INDEX NAME)

09/ 755,021


Absolute stereochemistry.



RN 220124-54-9 CAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-55-0 CAPLUS

CN Butanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-56-1 CAPLUS

CN Pentanamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220124-57-2 CAPLUS

CN Cyclopentaneacetamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-58-3 CAPLUS

CN Cyclopentanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-59-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-60-7 CAPLUS

CN Butanamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-61-8 CAPLUS

CN Butanamide, 2-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-62-9 CAPLUS

CN Butanamide, 3-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-63-0 CAPLUS

CN Butanamide, 4-(dimethylamino)-3-hydroxy-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-64-1 CAPLUS

CN Benzeneacetamide, .alpha.-(hydroxymethyl)-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

09/ 755,021

(CA INDEX NAME)


Absolute stereochemistry.



RN 220124-65-2 CAPLUS

CN Benzenacetamide, 3,4-dichloro-N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-66-3 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-67-4 CAPLUS

CN Benzenepropanamide, N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-68-5 CAPLUS

CN Benzenepropanamide, 2-chloro-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-69-6 CAPLUS

CN Benzenepropanamide, 3,4-dihydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-70-9 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1R)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220124-71-0 CAPLUS

CN Benzenepropanamide, 4-hydroxy-N-[(1R)-1-[[3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3,5-dinitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-72-1 CAPLUS

CN Benzenepropanamide, 2,3,4,5,6-pentafluoro-N-[(1R)-1-[[3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-73-2 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,2-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)


09/ 755,021

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-74-3 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-75-4 CAPLUS  
CN 2-Propenamide, 3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-76-5 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-(3-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.

09/ 755,021




RN 220124-77-6 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-78-7 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-79-8 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220124-80-1 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-[3-(phenylmethoxy)phenyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220124-81-2 CAPLUS

CN 2-Propenamide, 3-[2-(hexyloxy)phenyl]-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220124-82-3 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-[2-(phenylmethoxy)phenyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09/ 755,021



RN 220124-83-4 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-84-5 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-85-6 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-86-7 CAPLUS

CN Benzamide, 4-butoxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-87-8 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-88-9 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-89-0 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-90-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-91-4 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-92-5 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-93-6 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220124-94-7 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021




RN 220124-95-8 CAPLUS  
CN Benzeneacetamide, 2-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220124-96-9 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-97-0 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220124-98-1 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220124-99-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-00-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-01-9 CAPLUS

CN Benzenacetamide, 3,4-dichloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-02-0 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-03-1 CAPLUS

CN Benzenepropanamide, 2-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-04-2 CAPLUS

CN Benzenepropanamide, 3-hydroxy-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-05-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-06-4 CAPLUS

CN Acetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-07-5 CAPLUS

CN Propanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-08-6 CAPLUS

CN Propanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-09-7 CAPLUS

CN Cyclopentanecarboxamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-10-0 CAPLUS

09/ 755,021

CN Cyclopropanecarboxamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-1-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-11-1 CAPLUS

CN Butanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-12-2 CAPLUS

CN Pentanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-13-3 CAPLUS

CN Cyclopentaneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-14-4 CAPLUS

CN Cyclopentanecarboxamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220125-15-5P 220125-16-6P 220125-17-7P  
220125-18-8P 220125-19-9P 220125-20-2P  
220125-21-3P 220125-22-4P 220125-23-5P  
220125-24-6P 220125-25-7P 220125-26-8P  
220125-27-9P 220125-28-0P 220125-29-1P  
220125-30-4P 220125-31-5P 220125-32-6P  
220125-33-7P 220125-34-8P 220125-35-9P  
220125-36-0P 220125-37-1P 220125-38-2P  
220125-39-3P 220125-40-6P 220125-41-7P  
220125-42-8P 220125-43-9P 220125-44-0P  
220125-45-1P 220125-46-2P 220125-47-3P  
220125-48-4P 220125-49-5P 220125-50-8P  
220125-52-0P 220125-53-1P 220125-54-2P  
220125-55-3P 220125-56-4P 220125-57-5P  
220125-58-6P 220125-59-7P 220125-60-0P  
220125-61-1P 220125-69-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(prepn. of an opioid antagonist combinatorial library of acylaminoethylpiperidinylphenols)

RN 220125-15-5 CAPLUS

CN Cyclopropanecarboxamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-16-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-17-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-18-8 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-3-(2-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




09/ 755,021



RN 220125-19-9 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N,2,5-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-20-2 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-21-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-22-4 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-.beta.-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-23-5 CAPLUS

CN Benzenebutanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-. (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-24-6 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-methylethyl]-N-methyl-. (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021

RN 220125-25-7 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N,2-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220125-26-8 CAPLUS

CN 2-Propenamide, 3-(2-chlorophenyl)-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 220125-27-9 CAPLUS

CN 2-Propenamide, 3-(3-fluorophenyl)-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220125-28-0 CAPLUS

CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-3-(3-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

09/ 755,021


NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220125-29-1 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-3-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



RN 220125-30-4 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-3-(1-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220125-31-5 CAPLUS  
CN 2-Propenamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 755,021


Double bond geometry unknown.



RN 220125-32-6 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-33-7 CAPLUS

CN Benzamide, 2-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-34-8 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-2-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-35-9 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-36-0 CAPLUS

CN Benzeneacetamide, 2-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-37-1 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-38-2 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-.beta.-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-39-3 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-.alpha.-(phenylmethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 220125-40-6 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-41-7 CAPLUS

CN Benzenebutanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-42-8 CAPLUS

CN Benzamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-43-9 CAPLUS

CN Benzamide, 4-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 220125-44-0 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-45-1 CAPLUS

CN Benzeneacetamide, 3-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-46-2 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-47-3 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-48-4 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-49-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-50-8 CAPLUS

CN Benzenepropanamide, N-[(1S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylethyl]-4-methoxy-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-52-0 CAPLUS

CN Benzeneacetamide, 4-butoxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-53-1 CAPLUS

CN Benzanide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-54-2 CAPLUS

CN Benzamide, 2-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-55-3 CAPLUS

CN Benzamide, 3-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-56-4 CAPLUS

CN Benzamide, N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-phenoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-57-5 CAPLUS

CN Benzamide, 3-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-58-6 CAPLUS

CN Benzamide, 4-chloro-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220125-59-7 CAPLUS

CN Benzamide, 4-(dodecyloxy)-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 220125-60-0 CAPLUS

CN Benzamide, 4-butoxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-61-1 CAPLUS

CN Benzamide, 4-hydroxy-N-[2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220125-69-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-1-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:25399 CAPLUS

DOCUMENT NUMBER: 124:87442

TITLE: Synthesis of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists: application of the cis-thermal elimination of carbonates to alkaloid synthesis

AUTHOR(S): Werner, John A.; Cerbone, Louis R.; Frank, Scott A.; Ward, Jeffrey A.; Labib, Parviz; Tharp-Taylor, Roger W.; Ryan, C. W.

CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285-4813, USA

SOURCE: Journal of Organic Chemistry (1996), 61(2), 587-97  
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:87442

AB Improved syntheses of two trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists from 1,3-dimethyl-4-piperidinone are described. 1,3-Dimethyl-4-(3-isopropoxyphenyl)-piperidinol was selectively dehydrated in a two step process to the 1,3-dimethyl-4-(3-isopropoxyphenyl)-1,2,3,6-tetrahydropyridine (I) by the cis-thermal elimination of the corresponding alkyl carbonate deriv. at 190 .degree.C. In the presence of a basic nitrogen, the success of the elimination was found to be critically dependent upon the nature of the carbonate alkyl group, with Et, i-Bu, and i-Pr being preferred (90% yield). Alkylation of the metalloenamine, formed by deprotonation of I with n-BuLi, proceeded regio- and stereospecifically to give trans-3,4-dimethyl-4-(3-isopropoxyphenyl)-1,2,3,4-tetrahydropyridine, which was converted in three steps to the common intermediate, (3R,4R)-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine. LY255582, a centrally-active opioid antagonist, and LY246736-dihydrate, a peripherally-active opioid antagonist, were prepd. from 1,3-dimethyl-4-piperidinone in 11.8% yield (8 steps) and 6.2% yield (12 steps), resp.

IT 145603-86-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis of (hydroxyphenyl)piperidine opioid antagonists via thermal elimination of carbonates)

RN 145603-86-7 CAPLUS

CN Glycine, N-[(2S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

09/ 755,021




IT 156053-89-3P 170098-38-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of (hydroxyphenyl)piperidine opioid antagonists via thermal elimination of carbonates)

RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 170098-38-1 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, dihydrate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





L3 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1995:907624 CAPLUS

DOCUMENT NUMBER: 123:313767

TITLE: Preparation of 3,4,4-trisubstituted piperidinyl  
N-alkylcarboxylates and intermediates, useful as  
opioid antagonists.INVENTOR(S): Frank, Scott Alan; Prather, Douglas Edward; Ward,  
Jeffrey Alan; Werner, John Arnold

PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA

SOURCE: Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 657428	A1	19950614	EP 1994-308951	19941202
EP 657428	B1	20010404		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5434171	A	19950718	US 1993-164074	19931208
AU 9479170	A1	19950615	AU 1994-79170	19941201
AU 681198	B2	19970821		
JP 07215937	A2	19950815	JP 1994-298356	19941201
ZA 9409584	A	19960603	ZA 1994-9584	19941201
IL 111843	A1	20000229	IL 1994-111843	19941201
PL 181734	B1	20010928	PL 1994-306068	19941201
CZ 290559	B6	20020814	CZ 1994-2992	19941201
CA 2137221	AA	19950609	CA 1994-2137221	19941202
FI 9405703	A	19950609	FI 1994-5703	19941202
NO 9404644	A	19950609	NO 1994-4644	19941202
BR 9404842	A	19950808	BR 1994-4842	19941202
HU 71489	A2	19951128	HU 1994-3466	19941202
RU 2145958	C1	20000227	RU 1994-42903	19941202
EP 984004	A2	20000308	EP 1999-203390	19941202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT				
AT 200279	E	20010415	AT 1994-308951	19941202
ES 2155844	T3	20010601	ES 1994-308951	19941202
CN 1111239	A	19951108	CN 1994-119376	19941203
CN 1057294	B	20001011		
CN 1223257	A	19990721	CN 1998-123069	19981203
HK 1013826	A1	20020222	HK 1998-115194	19981223
FI 2000000353	A	20000217	FI 2000-353	20000217
PRIORITY APPLN. INFO.:				
			US 1993-164074	A 19931208
			EP 1994-308951	A3 19941202
OTHER SOURCE(S): CASREACT 123:313767; MARPAT 123:313767				
GI				



AB The invention relates to novel cryst. compds. I and II [R = C1-6 alkyl] and their salts, as well as processes for their prepn., and their use as intermediates and/or peripheral opioid antagonists. The HCl, HBr, succinate, and (+)-dibenzoyltartrate salts of I are stable, cryst., and when contaminated by the undesired (R,R,R) epimer, undergo diastereomeric enrichment by crystn. II.2H<sub>2</sub>O (R = H) and certain assocn. compds. of II (R = C1-6 alkyl), specifically the HCl-acetone solvate and the 1:1 and 3:2 malates, are useful for treatment of irritable bowel syndrome, idiopathic constipation, and non-ulcer dyspepsia. For example, condensation of I (R = H) with p-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H.H<sub>2</sub>NCH<sub>2</sub>CO<sub>2</sub>Bu-iso using DCC, HOBT, and Et<sub>3</sub>N in THF gave 95% II (R = Bu-iso). Hydrolysis of the latter compd. using NaOH in aq. EtOH at 25-30.degree., followed by neutralization and crystn. at pH 6.0, gave II.2H<sub>2</sub>O (R = H) in 85% yield. Compds. II had AD<sub>50</sub> of > 8 mg/kg in the morphine-inhibited mouse writhing test, but ED<sub>50</sub> of < 1 mg/kg in the mouse diarrhea test, indicating greater relative antagonism of peripheral opioid effects than central activity.

IT 156053-91-7P 170098-34-7P


RL: BYP (Byproduct); RCT (Reactant); REM (Removal or disposal); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)  
(byproduct; prepn. of piperidinyll alkylcarboxylates as opioid antagonists)

RN 156053-91-7 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, ethyl ester, [3R-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 170098-34-7 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, ethyl ester, hydrochloride, [3R-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 170098-32-5P 170098-33-6P


RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; prepn. of piperidinyl alkylcarboxylates as opioid antagonists)

RN 170098-32-5 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, ethyl ester, hydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



● HCl


RN 170098-33-6 CAPLUS  
CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, ethyl ester, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 170098-40-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; prepn. of piperidinyl alkylcarboxylates as opioid antagonists)  
RN 170098-40-5 CAPLUS  
CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-, ethyl ester, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 145603-86-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);


09/ 755,021

PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(product; prepn. of piperidiny l alkylcarboxylates as opioid  
antagonists)

RN 145603-86-7 CAPLUS

CN Glycine, N-[(2S)-2-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-  
piperidiny l]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 156053-89-3P 170098-30-3P 170098-31-4P

170098-37-0P 170098-38-1P 170098-51-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); IMF (Industrial manufacture); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)

(product; prepn. of piperidiny l alkylcarboxylates as opioid  
antagonists)

RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-  
piperidiny l]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 170098-30-3 CAPLUS

CN Glycine, N-[(2S)-2-[[ (3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-  
piperidiny l]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester,  
(2Z)-2-butenedioate (2:3) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 145603-86-7

09/ 755,021

CMF C29 H40 N2 O4

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 170098-31-4 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-methylethyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 170098-37-0 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-methylethyl ester, [3R-[1(S\*),3.alpha.,4.alpha.]]-

09/ 755,021


, compd. with 2-propanone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 170098-36-9

CMF C28 H38 N2 O4


Absolute stereochemistry.



CM 2

CRN 67-64-1


CMF C3 H6 O



RN 170098-38-1 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, dihydrate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● 2 H<sub>2</sub>O

RN 170098-51-8 CAPLUS


CN Glycine, N-[2-[[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, [3R-[1(S\*),3.alpha.,4.alpha.]]-, (S)-hydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

09/ 755,021

CRN 145603-86-7  
CMF C29 H40 N2 O4


Absolute stereochemistry.



CM 2


CRN 97-67-6  
CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).



L3 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 1994:457300 CAPLUS  
DOCUMENT NUMBER: 121:57300  
TITLE: Discovery of a potent, peripherally selective  
trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine  
opioid antagonist for the treatment of  
gastrointestinal motility disorders  
AUTHOR(S): Zimmerman, Dennis M.; Gidda, Jaswant S.; Cantrell,  
Buddy E.; Schoepp, Darryle D.; Johnson, Bryan G.;  
Leander, J. David  
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company,  
Indianapolis, IN, 46285, USA  
SOURCE: Journal of Medicinal Chemistry (1994), 37(15), 2261-5  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI





AB Structure-activity relationship studies were pursued within N-substituted-trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines in an effort to discover a peripherally selective opioid antagonist with high activity following systemic administration. Altering the size and the polarity of the N-substituent led to the discovery of I (LY246736). I has high affinity for opioid receptors ( $K_i = 0.77, 40, \text{ and } 4.4 \text{ nM}$  for  $\mu$ .,  $\kappa$ ., and  $\delta$ . receptors, resp.). It is a potent  $\mu$ . receptor antagonist following parenteral and oral administration and distributes selectively ( $>200$ -fold selectivity) to peripheral receptors. Thus, I has properties suitable for the clin. investigation of  $\mu$ . opioid receptor involvement in GI motility disorders.

IT 145590-95-0P 145603-86-7P 145603-87-8P  
145603-88-9P 156053-89-3P 156130-39-1P  
156130-40-4P 156130-43-7P 156130-44-8P  
170098-38-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and opioid antagonist activity of)

RN 145590-95-0 CAPLUS

CN Glycine, N-[(2R)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145603-86-7 CAPLUS

09/ 755,021

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 145603-87-8 CAPLUS

CN Glycine, N-[(2R)-2-[[[(3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145603-88-9 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 156053-89-3 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 156130-39-1 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, [1(R\*),3.alpha.,4.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 156130-40-4 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, [1(R\*),3.alpha.,4.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 156130-43-7 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, [1(S\*),3.alpha.,4.alpha.]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 156130-44-8 CAPLUS

CN Glycine, N-[(2R)-2-[[[(3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 170098-38-1 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, dihydrate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● 2 H<sub>2</sub>O


IT 156053-91-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and reaction of, in prepn. of hydroxyphenylpiperidinypropionyl aminoacetic acid)

RN 156053-91-7 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, ethyl ester, [3R-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1993:539107 CAPLUS

DOCUMENT NUMBER: 119:139107

TITLE: Preparation of phenylpiperidine derivatives as peripheral opioid antagonists.

INVENTOR(S): Cantrell, Buddy E.; Zimmerman, Dennis M.

PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA

SOURCE: Can. Pat. Appl., 157 pp.

CODEN: CPXXEB


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2064373	AA	19920930	CA 1992-2064373	19920327
PRIORITY APPLN. INFO.:			US 1991-667042	19910329
OTHER SOURCE(S):	MARPAT 119:139107			
GI				



AB Title compds. I (R<sub>1</sub> = H, C1-5 alkyl; R<sub>2</sub> = H, C1-5 alkyl, C2-6 alkenyl; R<sub>3</sub> = H, C1-10 alkyl, C3-10 alkenyl, Ph, phenyl-C1-3-alkyl, cycloalkyl, C5-8 cycloalkenyl, etc.; A = R<sub>4</sub>O, R<sub>6</sub>R<sub>5</sub>N wherein R<sub>4</sub> = H, C1-10 alkyl, C2-10 alkenyl, cycloalkyl, C5-8 cycloalkenyl, etc.; R<sub>5</sub> = H, C1-3 alkyl; R<sub>6</sub> = H, C1-10 alkyl, C3-10 alkenyl, cycloalkyl, Ph, C5-8 cycloalkenyl, oxadiazolylalkyl, (methyloxodioxolyl)methyl, etc.; n = 0-4), showing good peripheral .mu. opioid receptor antagonism, are prepd. These compds. are useful for the prevention of peripheral side effects assocd. with the use of opioid analgesics, including constipation, nausea, and vomiting. Trans-(+)-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (prepn. given) and H<sub>2</sub>C:C(EtO<sub>2</sub>C)CH<sub>2</sub>Ph in MeOH were stirred at room temp. to give trans-I (R<sub>1</sub> = H, R<sub>2</sub> = Me, R<sub>3</sub> = PhCH<sub>2</sub>, A = OEt, n = 1), isolated as the HCl salt. Pharmaceutical formulations comprising I are given.


IT **145603-87-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 145603-87-8 CAPLUS

CN Glycine, N-[(2R)-2-[(3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




IT 145590-01-8P 145590-03-0P 145590-29-0P  
 145590-30-3P 145590-32-5P 145590-33-6P  
 145590-34-7P 145590-35-8P 145590-36-9P  
 145590-37-0P 145590-38-1P 145590-39-2P  
 145590-40-5P 145590-41-6P 145590-42-7P  
 145590-43-8P 145590-44-9P 145590-45-0P  
 145590-46-1P 145590-47-2P 145590-48-3P  
 145590-49-4P 145590-50-7P 145590-51-8P  
 145590-52-9P 145590-53-0P 145590-54-1P  
 145590-55-2P 145590-56-3P 145590-57-4P  
 145590-58-5P 145590-59-6P 145590-60-9P  
 145590-61-0P 145590-62-1P 145590-63-2P  
 145590-64-3P 145590-65-4P 145590-66-5P  
 145590-67-6P 145590-68-7P 145590-69-8P  
 145590-71-2P 145590-72-3P 145590-74-5P  
 145590-76-7P 145590-83-6P 145590-84-7P  
 145590-85-8P 145590-86-9P 145590-87-0P  
 145590-88-1P 145590-89-2P 145590-90-5P  
 145590-91-6P 145590-92-7P 145590-93-8P  
 145590-95-0P 145591-02-2P 145591-04-4P  
 145591-24-8P 145591-25-9P 145591-26-0P  
 145591-28-2P 145591-29-3P 145591-30-6P  
 145591-31-7P 145591-32-8P 145591-33-9P  
 145591-34-0P 145591-35-1P 145591-36-2P  
 145591-37-3P 145591-38-4P 145591-39-5P  
 145591-40-8P 145591-41-9P 145591-42-0P  
 145591-43-1P 145591-44-2P 145591-45-3P  
 145591-46-4P 145591-47-5P 145591-48-6P  
 145591-49-7P 145591-50-0P 145591-51-1P  
 145591-52-2P 145591-53-3P 145591-54-4P  
 145591-55-5P 145591-56-6P 145591-61-3P  
 145591-62-4P 145591-63-5P 145591-64-6P  
 145591-65-7P 145591-66-8P 145591-67-9P  
 145591-68-0P 145591-69-1P 145591-70-4P  
 145591-71-5P 145603-86-7P 145603-88-9P  
 145609-45-6P 149541-66-2P 149541-67-3P  
 149541-69-5P 149541-70-8P 149541-71-9P  
 149541-72-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as peripheral opioid antagonist)

RN 145590-01-8 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-  
 (phenylmethyl)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




HCl

09/ 755,021


RN 145590-03-0 CAPLUS

CN 1-Piperidinepropanoic acid, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



RN 145590-29-0 CAPLUS

CN Glycine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 145590-30-3 CAPLUS

CN Glycine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




09/ 755,021



RN 145590-32-5 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-(methylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 145590-33-6 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021




RN 145590-34-7 CAPLUS  
CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 145590-35-8 CAPLUS  
CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021




RN 145590-36-9 CAPLUS  
CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI)  
(CA INDEX NAME)




RN 145590-37-0 CAPLUS  
CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

09/ .755,021



RN 145590-38-1 CAPLUS


CN 1-Piperidinepropanamide, N-(3-amino-3-oxopropyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 145590-39-2 CAPLUS


CN Butanoic acid, 4-[[[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021



RN 145590-40-5 CAPLUS


CN 1-Piperidinepropanamide, N-(4-amino-4-oxobutyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 145590-41-6 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021



RN 145590-42-7 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[4-(ethylamino)-4-oxobutyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 145590-43-8 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl


RN 145590-44-9 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 145590-45-0 CAPLUS


CN 1-Piperidinepropanamide, N-[2-(ethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145590-46-1 CAPLUS


CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021



● HCl

RN 145590-47-2 CAPLUS  
CN 1-Piperidinepropanamide, N-[2-(dimethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride  
(9CI) (CA INDEX NAME)




● HCl

RN 145590-48-3 CAPLUS  
CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(1-methylethyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)-, monohydrochloride  
(9CI) (CA INDEX NAME)




09/ 755,021



● HCl

RN 145590-49-4 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-oxo-2-(phenylmethyl)-1-(propylamino)ethyl]-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-50-7 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(2-methylpropyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-51-8 CAPLUS



CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 145590-52-9 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, cyclohexyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-53-0 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, cyclohexylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-54-1 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, monohydrochloride (9CI) (CA INDEX NAME)


CC1(C)CCN(CC1)CC(=O)C(Cc2ccccc2)C(=O)NCC(=O)OCC

RN	145590-55-2	CAPLUS
CN	Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)	



RN 145590-56-3 CAPLUS  
CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-57-4 CAPLUS


CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 145590-58-5 CAPLUS

CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-59-6 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[3-(methylamino)-3-oxopropyl]-.alpha.-(phenylmethyl)-, monohydrochloride  
(9CI) (CA INDEX NAME)




● HCl

RN 145590-60-9 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride  
(9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-61-0 CAPLUS

CN Butanoic acid, 4-[[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-62-1 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




09/ 755,021



● HCl

RN 145590-63-2 CAPLUS

CN 1-Piperidinepropanamide, N-(4-amino-4-oxobutyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-64-3 CAPLUS

CN 1-Piperidinepropanamide, N-[4-(ethylamino)-4-oxobutyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-65-4 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-N-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-66-5 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-N-methyl- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145590-67-6 CAPLUS


CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-68-7 CAPLUS

CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]- (9CI) (CA INDEX NAME)




RN 145590-69-8 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(dimethylamino)ethyl]-4-(3-hydroxyphenyl)-


09/ 755,021

3,4-dimethyl-.alpha.-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 145590-71-2 CAPLUS  
CN 1-Piperidinepropanamide, N-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 145590-72-3 CAPLUS  
CN Glycinamide, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021



● HCl


RN 145590-74-5 CAPLUS  
CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-N-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-76-7 CAPLUS  
CN Glycinamide, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-83-6 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methoxy-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-84-7 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, pentyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-85-8 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-amino-2-oxoethyl ester, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 145590-86-9 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(methylamino)-2-oxoethyl ester, monohydrochloride (9CI)  
(CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-87-0 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(ethylamino)-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-88-1 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(dimethylamino)-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)







● HCl

RN 145590-89-2 CAPLUS  
 CN 1-Piperidinepropanamide, N-[2-[(cyclohexylmethyl)amino]-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride  
 (9CI) (CA INDEX NAME)


PAGE 1-A






● HCl


RN 145590-90-5 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 4-methoxycyclohexyl ester, monohydrochloride (9CI)  
 (CA INDEX NAME)





● HCl


RN 145590-91-6 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-oxo-2-[(phenylmethyl)amino]ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-92-7 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-(acetyloxy)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-93-8 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-95-0 CAPLUS

CN Glycine, N-[(2R)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021



RN 145591-02-2 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 145591-04-4 CAPLUS


CN 1-Piperidinepropanoic acid, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-24-8 CAPLUS


CN Glycine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 145591-25-9 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-26-0 CAPLUS


CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 145591-28-2 CAPLUS


CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-29-3 CAPLUS

CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 145591-30-6 CAPLUS

CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)




09/ 755,021



RN 145591-31-7 CAPLUS


CN 1-Piperidinepropanamide, N-(3-amino-3-oxopropyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 145591-32-8 CAPLUS


CN Butanoic acid, 4-[[[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-33-9 CAPLUS


CN 1-Piperidinepropanamide, N-(4-amino-4-oxobutyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 145591-34-0 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-35-1 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[4-(ethylamino)-4-oxobutyl]-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 145591-36-2 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-37-3 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-38-4 CAPLUS


CN 1-Piperidinepropanamide, N-[2-(dimethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-39-5 CAPLUS


CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(1-methylethyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-40-8 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-oxo-2-(propylamino)ethyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-41-9 CAPLUS


CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(2-methylpropyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 145591-42-0 CAPLUS

CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


09/ 755,021



RN 145591-43-1 CAPLUS  
CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 145591-44-2 CAPLUS  
CN 1-Piperidinepropanamide, N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 145591-45-3 CAPLUS  
CN Butanoic acid, 4-[[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-46-4 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-47-5 CAPLUS


CN 1-Piperidinepropanamide, N-(4-amino-4-oxobutyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-48-6 CAPLUS


CN 1-Piperidinepropanamide, N-[4-(ethylamino)-4-oxobutyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-49-7 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 145591-50-0 CAPLUS

CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 145591-51-1 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(dimethylamino)ethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




09/ 755,021




RN 145591-52-2 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[3-(methylamino)-3-oxopropyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-53-3 CAPLUS


CN 1-Piperidinepropanamide, N-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-54-4 CAPLUS


CN Glycinamide, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-55-5 CAPLUS

CN Glycine, N-[N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 145591-56-6 CAPLUS


CN Glycinamide, N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl-N-ethyl- (9CI) (CA INDEX NAME)



RN 145591-61-3 CAPLUS


CN Glycine, N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methoxy-2-oxoethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-62-4 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, pentyl ester (9CI) (CA INDEX NAME)



RN 145591-63-5 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-amino-2-oxoethyl ester (9CI) (CA INDEX NAME)



RN 145591-64-6 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(methylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-65-7 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(ethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)





RN 145591-66-8 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(dimethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)





RN 145591-67-9 CAPLUS

CN 1-Piperidinepropanamide, N-[2-[(cyclohexylmethyl)amino]-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 145591-68-0 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 4-methoxycyclohexyl ester (9CI) (CA INDEX NAME)




RN 145591-69-1 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-oxo-2-[(phenylmethyl)amino]ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-70-4 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-(acetyloxy)ethyl ester (9CI) (CA INDEX NAME)



RN 145591-71-5 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (9CI) (CA INDEX NAME)




RN 145603-86-7 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145603-88-9 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145609-45-6 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[2-(ethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



09/ 755,021




RN 149541-66-2 CAPLUS  
CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 149541-67-3 CAPLUS  
CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[2-(ethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



09/ 755,021





RN 149541-69-5 CAPLUS  
CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 149541-70-8 CAPLUS  
CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, cyclohexylmethyl ester (9CI) (CA INDEX NAME)



RN 149541-71-9 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, cyclohexyl ester (9CI) (CA INDEX NAME)




RN 149541-72-0 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1993:212896 CAPLUS  
 DOCUMENT NUMBER: 118:212896  
 TITLE: Preparation and formulation of N-[(acylamino)alkyl]-4-(3-hydroxyphenyl)piperidines and analogs as peripheral opioid antagonists  
 INVENTOR(S): Cantrell, Buddy Eugene; Zimmerman, Dennis Michael  
 PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA  
 SOURCE: Eur. Pat. Appl., 77 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 506468	A1	19920930	EP 1992-302729	19920327
EP 506468	B1	19950426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE				
US 5159081	A	19921027	US 1991-677708	19910329
CA 2064382	AA	19920930	CA 1992-2064382	19920327
JP 05097807	A2	19930420	JP 1992-70803	19920327
JP 3059292	B2	20000704		
ES 2072096	T3	19950701	ES 1992-302729	19920327
US 5270328	A	19931214	US 1992-905940	19920629
PRIORITY APPLN. INFO.:			US 1991-677708	A 19910329
OTHER SOURCE(S):	MARPAT 118:212896			
GI				



AB R(CH<sub>2</sub>)<sub>n</sub>CHR<sub>3</sub>NR<sub>4</sub>R<sub>5</sub> [I; R = hydroxyphenylpiperidino group Q; R<sub>1</sub> = H, alkyl; R<sub>2</sub> = H, alkyl, alkenyl; R<sub>3</sub> = H, (cyclo)alkyl, (cyclo)alkenyl, Ph, phenylalkyl, etc.; R<sub>4</sub> = (cyclo)alkyl, alkenyl, Ph, phenylalkyl, etc.; R<sub>5</sub> = H, alkyl, alkanoyl, alkylcarbonyl, [CO(CH<sub>2</sub>)<sub>m</sub>CO]qR<sub>6</sub>, etc.; n, m, q = 1-3; R<sub>6</sub> = OH, alkoxy, NH<sub>2</sub>, alkylamino, etc.] were prepd. Thus, cyclohexylacetaldehyde was condensed with CH<sub>2</sub>(CO<sub>2</sub>H)<sub>2</sub> in the presence of NH<sub>4</sub>OAc and the protected product condensed with trans-QH (R<sub>2</sub> = Me, R<sub>1</sub> = H) to give, after deprotection and redn., QCH<sub>2</sub>CH<sub>2</sub>CHR<sub>3</sub>NH<sub>2</sub> (R<sub>3</sub> = cyclohexylmethyl) which was condensed with succinic anhydride to give Q(CH<sub>2</sub>)<sub>m</sub>CHR<sub>3</sub>NHCO(CH<sub>2</sub>)<sub>n</sub>COR<sub>6</sub> (R<sub>1</sub> = H, R<sub>3</sub> = cyclohexylmethyl) (II; R<sub>2</sub> = Me, R<sub>6</sub> = OH, m = n = 2). II (R<sub>2</sub> = Me, R<sub>6</sub> = OCH<sub>2</sub>CHMe<sub>2</sub>, n = 3, m = 1) had ED<sub>50</sub> of 0.002 mg/kg s.c. or orally for pptn. of opiate abstinence in mice.


IT 145340-77-8P 145340-78-9P 145340-79-0P  
 145340-80-3P 145340-81-4P 145340-82-5P  
 145340-84-7P 145340-85-8P 145340-86-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and reaction of, in prepn. of peripheral opioid antagonists)

RN 145340-77-8 CAPLUS  
 CN Phenol, 3-[1-[2-[(cyclohexylmethyl)amino]ethyl]-3,4-dimethyl-4-

09/ 755,021

piperidinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145340-78-9 CAPLUS

CN Cyclohexanecarboxamide, N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145340-79-0 CAPLUS

CN Phenol, 3-[1-[3-[(cyclohexylmethyl)amino]propyl]-3,4-dimethyl-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145340-80-3 CAPLUS

CN Phenol, 3-[3,4-dimethyl-1-[2-[(3-methylbutyl)amino]ethyl]-4-piperidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 145340-81-4 CAPLUS


CN Phenol, 3-[3,4-dimethyl-1-[3-[(2-methylpropyl)amino]propyl]-4-piperidinyloxy]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 145340-82-5 CAPLUS

CN Acetamide, N-[3-[4-[3-(acetyloxy)phenyl]-3,4-dimethyl-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)




RN 145340-84-7 CAPLUS

CN Propanoic acid, 3-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-3-oxo-, ethyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



● HCl

RN 145340-85-8 CAPLUS  
CN Glycine, N-[3-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-1,3-dioxopropyl]-, ethyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 145340-86-9 CAPLUS  
CN L-Leucine, N-[4-[[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]phenylamino]-1,4-dioxobutyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as peripheral opioid antagonist)

RN 145339-59-9 CAPLUS


CN Butanoic acid, 4-[[1-(cyclohexylmethyl)-3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145339-60-2 CAPLUS

CN Butanoic acid, 4-[[1-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methylbutyl]amino]-4-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145339-61-3 CAPLUS

CN Butanoic acid, 4-[[1-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methylbutyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)


09/ 755,021



RN 145339-62-4 CAPLUS

CN Pentanoic acid, 5-[[1-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methylbutyl]amino]-5-oxo-, ethyl ester, monohydrochloride, [1(R\*),3.alpha.,4.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 145339-63-5 CAPLUS

CN Pentanoic acid, 5-[[1-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methylbutyl]amino]-5-oxo-, ethyl ester, monohydrochloride, [1(S\*),3.alpha.,4.alpha.]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



● HCl

RN 145339-64-6 CAPLUS


CN Pentanoic acid, 5-[[1-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-3-methylbutyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



RN 145339-65-7 CAPLUS


CN Pentanoic acid, 5-[[1-cyclohexyl-3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl]amino]-5-oxo- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145339-66-8 CAPLUS

CN Pentanoic acid, 5-[[1-cyclohexyl-3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl]amino]-5-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145339-67-9 CAPLUS


CN Acetamide, N-[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145339-68-0 CAPLUS

CN Pentanoic acid, 5-[[[1-(cyclohexylmethyl)-3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl]amino]-5-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145339-69-1 CAPLUS


CN Pentanediamide, N-[1-[[[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylpropyl]amino]carbonyl]-4-[[imino(nitroamino)methyl]amino]butyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145339-70-4 CAPLUS

CN Pentanamide, N-[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]-1-phenylpropyl]-5-[[imino(nitroamino)methyl]amino]-2-[[4-[(2-methyl-1-oxopropyl)amino]-1-oxobutyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145339-71-5 CAPLUS

CN Propanoic acid, 3-[[1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]amino]-3-oxo-, ethyl ester, monohydrochloride, [3R-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145339-72-6 CAPLUS

CN Propanoic acid, 3-[[1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]amino]-3-oxo-, [3R-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145339-73-7 CAPLUS

CN Propanoic acid, 3-[[1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]amino]-3-oxo-, ethyl ester, monohydrochloride, [3S-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 145339-74-8 CAPLUS

CN Propanoic acid, 3-[[1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]amino]-3-oxo-, [3S-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145339-75-9 CAPLUS


CN Butanoic acid, 4-[[1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

09/ 755,021




RN 145339-76-0 CAPLUS

CN Pentanoic acid, 5-[[[1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



RN 145339-77-1 CAPLUS


CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



RN 145339-79-3 CAPLUS

CN Carbamic acid, [4-[[[1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-phenylethyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021




● HCl

RN 145339-80-6 CAPLUS

CN Butanoic acid, 4-[[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]phenylamino]-4-oxo-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145339-81-7 CAPLUS

CN Pentanoic acid, 5-[[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]phenylamino]-5-oxo-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145339-82-8 CAPLUS

CN Butanoic acid, 4-[cyclopentyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 145339-83-9 CAPLUS

CN Pentanoic acid, 5-[cyclohexyl[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl]amino]-5-oxo-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145339-84-0 CAPLUS

CN Butanoic acid, 4-[(cyclohexylmethyl)[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145339-85-1 CAPLUS

CN Pentanoic acid, 5-[(cyclohexylmethyl)[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl]amino]-5-oxo-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 145339-86-2 CAPLUS

CN Butanoic acid, 4-[[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl](3-methylbutyl)amino]-4-oxo-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145339-87-3 CAPLUS

CN Pentanoic acid, 5-[[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl](2-methylpropyl)amino]-5-oxo-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145339-88-4 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, 1-methylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


09/ 755,021



RN 145339-89-5 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, propyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145339-90-8 CAPLUS

CN Pentanoic acid, 5-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-5-oxo-, ethyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



HCl


RN 145339-91-9 CAPLUS

CN Pentanoic acid, 5-[cyclohexyl[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-

09/ 755,021

piperidinyl]propyl]amino]-5-oxo-, ethyl ester, monohydrochloride, cis-  
(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 145339-92-0 CAPLUS

CN Propanediamide, N-cyclohexyl-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145339-93-1 CAPLUS

CN Propanediamide, N-cyclohexyl-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

09/ 755,021




● HCl

RN 145339-94-2 CAPLUS

CN Butanediamide, N-cyclohexyl-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145339-95-3 CAPLUS

CN Butanediamide, N-cyclohexyl-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



09/ 755,021




● HCl

RN 145339-96-4 CAPLUS

CN Propanediamide, N-cyclohexyl-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N'-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145339-97-5 CAPLUS

CN Propanediamide, N-cyclohexyl-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N'-methyl-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

09/ 755,021




● HCl

RN 145339-98-6 CAPLUS

CN Pentanediamide, N-cyclohexyl-N-[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145339-99-7 CAPLUS

CN Pentanediamide, N-cyclohexyl-N-[3-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]propyl]-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




HCl

RN 145340-00-7 CAPLUS

09/ 755,021

CN Propanediamide, N-cyclohexyl-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-N'-[2-(methylamino)-2-oxoethyl]-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 145340-01-8 CAPLUS

CN L-Leucine, N-[4-[[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]phenylamino]-1,4-dioxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 145340-02-9 CAPLUS

CN Butanamide, N-cyclohexyl-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-4-[(3-methyl-1-oxobutyl)amino]-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

09/ 755,021




● HCl

RN 145340-03-0 CAPLUS


CN L-Phenylalanine, N-[4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyloxy]ethyl]amino]-1,4-dioxobutyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 145340-04-1 CAPLUS


CN Pentanamide, 2-(acetylamino)-N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyloxy]ethyl]-5-[[imino(nitroamino)methyl]amino]- (9CI) (CA INDEX NAME)



RN 145340-05-2 CAPLUS


09/ 755,021

CN Pentanamide, N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]-5-  
[[imino(nitroamino)methyl]amino]-2-[(3-methyl-1-oxobutyl)amino]- (9CI)  
(CA INDEX NAME)



RN 145340-06-3 CAPLUS

CN Carbamic acid, [1-[[[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]carbonyl]-4-[[imino(nitroamino)methyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 145340-07-4 CAPLUS

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145340-08-5 CAPLUS

CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, [3R-[1(R\*),3.alpha.,4.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145340-09-6 CAPLUS

CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, [3S-[1(R\*),3.alpha.,4.alpha.]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021



RN 145340-10-9 CAPLUS  
CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, [3S-[1(S\*),3.alpha.,4.alpha.]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145340-11-0 CAPLUS  
CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, methyl ester, monohydrochloride, [3S-[1(R\*),3.alpha.,4.alpha.]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145340-12-1 CAPLUS

CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, methyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145340-13-2 CAPLUS

CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, ethyl ester, monohydrochloride, [3S-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 145340-14-3 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, ethyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145340-15-4 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, propyl ester, monohydrochloride, [3S-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021



RN 145340-16-5 CAPLUS  
CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, propyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145340-17-6 CAPLUS  
CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-methylpropyl ester, monohydrochloride, [3S-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021



RN 145340-18-7 CAPLUS  
CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-methylpropyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145340-19-8 CAPLUS  
CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, heptyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145340-20-1 CAPLUS

CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-methylpropyl ester, monohydrochloride, [3S-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145340-21-2 CAPLUS

CN Pentanoic acid, 5-[[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-methylpropyl ester, monohydrochloride, [3R-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021



RN 145340-22-3 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-amino-2-oxoethyl ester, monohydrochloride, [3S-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 145340-23-4 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-amino-2-oxoethyl ester, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145340-24-5 CAPLUS

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidiny]methyl]ethyl]amino]-5-oxo-, 2-amino-2-oxoethyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 145340-25-6 CAPLUS

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidiny]methyl]ethyl]amino]-5-oxo-, 2-(methylamino)-2-oxoethyl ester, [3S-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145340-26-7 CAPLUS

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-(methylamino)-2-oxoethyl ester, monohydrochloride, [3S-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 145340-27-8 CAPLUS

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-(methylamino)-2-oxoethyl ester, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CC(=O)N[C@H](Cc1ccccc1)S[C@H](CN2CC[C@H](C2)C(C)(C)c3ccc(O)cc3)CCOC(=O)CC(=O)N


CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-(methylamino)-2-oxoethyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidiny]methyl]ethyl]amino]-5-oxo-, 2-(dimethylamino)-2-oxoethyl ester, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 145340-30-3 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-(dimethylamino)-2-oxoethyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 145340-31-4 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-(ethylamino)-2-oxoethyl ester, [3S-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145340-32-5 CAPLUS

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-(ethylamino)-2-oxoethyl ester, monohydrochloride, [3S-[1(R\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 145340-33-6 CAPLUS

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-(ethylamino)-2-oxoethyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021




● HCl

RN 145340-34-7 CAPLUS  
 CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 1-(acetyloxy)ethyl ester (9CI)  
 (CA INDEX NAME)




RN 145340-35-8 CAPLUS  
 CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 1-(acetyloxy)ethyl ester,  
 monohydrochloride (9CI) (CA INDEX NAME)



RN 145340-36-9 CAPLUS

CN Pentanoic acid, 5-[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 145340-37-0 CAPLUS

CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, monohydrochloride, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

09/ 755,021




● HCl

RN 145340-38-1 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, ethyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145340-39-2 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, ethyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 145340-40-5 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, 2-methylpropyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145340-41-6 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, 2-methylpropyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

09/ 755,021




● HCl

RN 145340-42-7 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, cyclohexylmethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145340-43-8 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, cyclohexylmethyl ester, monohydrochloride, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 755,021



● HCl

RN 145340-83-6 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145340-99-4 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 2-(ethylamino)-2-oxoethyl ester, [3R-[1(S\*),3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 755,021



RN 145361-59-7 CAPLUS

CN Propanoic acid, 3-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-3-oxo-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 145361-60-0 CAPLUS

CN Butanoic acid, 4-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-4-oxo-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 145361-61-1 CAPLUS

CN Pentanoic acid, 5-[cyclohexyl[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]ethyl]amino]-5-oxo-, cis- (9CI) (CA INDEX NAME)

09/ 755,021

Relative stereochemistry.




RN 146429-09-6 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, 3(or 4)-methoxycyclohexyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-Me

PAGE 2-A




RN 146502-74-1 CAPLUS  
CN Pentanoic acid, 5-[[2-cyclohexyl-1-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]ethyl]amino]-5-oxo-, methoxycyclohexyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-Me

PAGE 2-A




L3 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1993:124401 CAPLUS  
 DOCUMENT NUMBER: 118:124401  
 TITLE: Preparation of .omega.-(4-phenylpiperidino)alkanoates  
 as peripheral opioid receptor antagonists  
 INVENTOR(S): Cantrell, Buddy Eugene; Zimmerman, Denis Michael  
 PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA  
 SOURCE: Eur. Pat. Appl., 79 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 506478	A1	19920930	EP 1992-302751	19920327
EP 506478	B1	19970903		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
ZA 9202180	A	19930927	ZA 1992-2180	19920325
CZ 284993	B6	19990414	CZ 1992-902	19920325
NO 9201182	A	19920930	NO 1992-1182	19920326
NO 178398	B	19951211		

09/ 755,021

NO 178398	C	19960320		
HU 66596	A2	19941228	HU 1992-1013	19920326
IL 101382	A1	19970415	IL 1992-101382	19920326
AU 9213880	A1	19921001	AU 1992-13880	19920327
AU 644051	B2	19931202		
BR 9201084	A	19921124	BR 1992-1084	19920327
JP 05097806	A2	19930420	JP 1992-70790	19920327
JP 3056321	B2	20000626		
RU 2076863	C1	19970410	RU 1992-5011276	19920327
AT 157653	E	19970915	AT 1992-302751	19920327
ES 2106825	T3	19971116	ES 1992-302751	19920327
CN 1065455	A	19921021	CN 1992-102213	19920328
CN 1041309	B	19981223		
US 5250542	A	19931005	US 1992-916783	19920717
PRIORITY APPLN. INFO.:			US 1991-677042	A 19910329
OTHER SOURCE(S):		MARPAT 118:124401		
GI				




AB Title compds. I (R1 = H, C1-5 alkyl; R2 = H, C1-3 alkyl, C2-6 alkenyl; R3 = H, C1-10 alkyl, C1-10 alkenyl, Ph, cycloalkyl, etc.; A = R4O, R6R5N wherein R4 = H, C1-10 alkyl, C2-10 alkenyl, cycloalkyl, etc., R5 = H, C1-3 alkyl, R6 = H, C1-10 alkyl, C3-10 alkenyl, cycloalkyl, Ph, HO2C(CH2)3NH, etc., R5R6 are each CH2 which together with N form 4-6-membered heterocyclyl, etc., n = 0-4) or a part thereof, useful as peripheral opioid antagonists, are prepd. I.HCl (R1 = H, R2 = Me, R3 = cyclohexyl, n = 2, A = HO) (prepn. given), H2N(CH2)3CO2Et.HCl and Et3N in DMF were combined with DCC to give I [R1 = H, R2 = Me, R3 = cyclohexyl, n = 2, A = EtO2C(CH2)3NH].HCl which was converted to the free acid (II). II showed the greatest antagonism of the peripheral opioid receptors. Pharmaceutical formulations comprising I are given.

IT 145591-02-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and conversion to diastereomers)

RN 145591-02-2 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




IT 145590-01-8P 145590-03-0P 145590-29-0P

145590-30-3P 145590-31-4P 145590-32-5P  
 145590-33-6P 145590-34-7P 145590-35-8P  
 145590-36-9P 145590-37-0P 145590-38-1P  
 145590-39-2P 145590-40-5P 145590-41-6P  
 145590-42-7P 145590-43-8P 145590-44-9P  
 145590-45-0P 145590-46-1P 145590-47-2P  
 145590-48-3P 145590-49-4P 145590-50-7P  
 145590-51-8P 145590-52-9P 145590-53-0P  
 145590-54-1P 145590-55-2P 145590-56-3P  
 145590-57-4P 145590-58-5P 145590-59-6P  
 145590-60-9P 145590-61-0P 145590-62-1P  
 145590-63-2P 145590-64-3P 145590-65-4P  
 145590-66-5P 145590-67-6P 145590-68-7P  
 145590-69-8P 145590-71-2P 145590-72-3P  
 145590-74-5P 145590-76-7P 145590-83-6P  
 145590-84-7P 145590-85-8P 145590-86-9P  
 145590-87-0P 145590-88-1P 145590-89-2P  
 145590-90-5P 145590-91-6P 145590-92-7P  
 145590-93-8P 145590-95-0P 145591-03-3P  
 145591-04-4P 145591-24-8P 145591-25-9P  
 145591-26-0P 145591-28-2P 145591-29-3P  
 145591-30-6P 145591-31-7P 145591-32-8P  
 145591-33-9P 145591-34-0P 145591-35-1P  
 145591-36-2P 145591-37-3P 145591-38-4P  
 145591-39-5P 145591-40-8P 145591-41-9P  
 145591-42-0P 145591-43-1P 145591-44-2P  
 145591-45-3P 145591-46-4P 145591-47-5P  
 145591-48-6P 145591-49-7P 145591-50-0P  
 145591-51-1P 145591-52-2P 145591-53-3P  
 145591-54-4P 145591-55-5P 145591-56-6P  
 145591-61-3P 145591-62-4P 145591-63-5P  
 145591-64-6P 145591-65-7P 145591-66-8P  
 145591-67-9P 145591-68-0P 145591-69-1P  
 145591-70-4P 145591-71-5P 145603-86-7P  
 145603-87-8P 145603-88-9P 145609-45-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as opioid receptor antagonist)

RN 145590-01-8 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-  
 (phenylmethyl)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




HCl

RN 145590-03-0 CAPLUS

CN 1-Piperidinepropanoic acid, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-


09/ 755,021

3,4-dimethyl-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



RN 145590-29-0 CAPLUS


CN Glycine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI)  
(CA INDEX NAME)



RN 145590-30-3 CAPLUS


CN Glycine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145590-31-4 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(ethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-32-5 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-(methylamino)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021



RN 145590-33-6 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 145590-34-7 CAPLUS


CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



09/ 755,021




RN 145590-35-8 CAPLUS  
CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 145590-36-9 CAPLUS  
CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021




RN 145590-37-0 CAPLUS  
CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 145590-38-1 CAPLUS  
CN 1-Piperidinepropanamide, N-(3-amino-3-oxopropyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021



RN 145590-39-2 CAPLUS


CN Butanoic acid, 4-[[[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 145590-40-5 CAPLUS

CN 1-Piperidinepropanamide, N-(4-amino-4-oxobutyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021




RN 145590-41-6 CAPLUS  
CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-  
3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-, monohydrochloride (9CI) (CA  
INDEX NAME)




RN 145590-42-7 CAPLUS  
CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[4-(ethylamino)-4-  
oxobutyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-, monohydrochloride (9CI) (CA  
INDEX NAME)

09/ 755,021




RN 145590-43-8 CAPLUS  
CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 145590-44-9 CAPLUS  
CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

09/ 755,021




RN 145590-45-0 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(ethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145590-46-1 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-47-2 CAPLUS

CN 1-Piperidinepropanamide, N-[2-(dimethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride

09/ 755,021


(9CI) (CA INDEX NAME)



● HCl

RN 145590-48-3 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(1-methylethyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)-, monohydrochloride  
(9CI) (CA INDEX NAME)




● HCl

RN 145590-49-4 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-oxo-2-(propylamino)ethyl]-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-50-7 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(2-methylpropyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-51-8 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)







● HCl

RN 145590-52-9 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, cyclohexyl ester, monohydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A






● HCl


RN 145590-53-0 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, cyclohexylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)





● HCl


RN 145590-54-1 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-55-2 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-56-3 CAPLUS

CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-57-4 CAPLUS


CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145590-58-5 CAPLUS

CN .beta.-Alanine, N-[2-[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-59-6 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[3-(methylamino)-3-oxopropyl]-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-60-9 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-61-0 CAPLUS

CN Butanoic acid, 4-[[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


CC1(C)CCCCN1CC(=O)C(Cc2ccccc2)C(=O)NCCCCC(=O)OCC

RN	145590-62-1	CAPLUS
CN	1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-.alpha.-(phenylmethyl)-, monohydrochloride (9CI)	
	(CA INDEX NAME)	



RN	145590-63-2	CAPLUS
CN	1-Piperidinepropanamide, N-(4-amino-4-oxobutyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)	


09/ 755,021



● HCl

RN 145590-64-3 CAPLUS

CN 1-Piperidinepropanamide, N-[4-(ethylamino)-4-oxobutyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-65-4 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-N-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




09/ 755,021



● HCl

RN 145590-66-5 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 145590-67-6 CAPLUS


CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

RN 145590-68-7 CAPLUS  
CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]- (9CI) (CA INDEX NAME)




RN	145590-69-8	CAPLUS
CN	1-Piperidinepropanamide, N-[2-(dimethylamino)ethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)	

09/ 755,021




● 2 HCl

RN 145590-71-2 CAPLUS  
CN 1-Piperidinepropanamide, N-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-72-3 CAPLUS  
CN Glycinamide, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

09/ 755,021

RN 145590-74-5 CAPLUS


CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-N-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-76-7 CAPLUS

CN Glycinamide, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-83-6 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methoxy-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-84-7 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, pentyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-85-8 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-amino-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-86-9 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(methylamino)-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 145590-87-0 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(ethylamino)-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


09/ 755,021



● HCl

RN 145590-88-1 CAPLUS



CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(dimethylamino)-2-oxoethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-89-2 CAPLUS



CN 1-Piperidinepropanamide, N-[2-[(cyclohexylmethyl)amino]-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 145590-90-5 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 4-methoxycyclohexyl ester, monohydrochloride (9CI)  
 (CA INDEX NAME)






● HCl


RN 145590-91-6 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-oxo-2-[(phenylmethyl)amino]ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021



● HCl


RN 145590-92-7 CAPLUS  
CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-(acetyloxy)ethyl ester, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

RN 145590-93-8 CAPLUS  
CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

09/ 755,021




● HCl

RN 145590-95-0 CAPLUS


CN Glycine, N-[(2R)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 145591-03-3 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 145591-04-4 CAPLUS

CN 1-Piperidinepropanoic acid, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-


09/ 755,021

3,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 145591-24-8 CAPLUS


CN Glycine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 145591-25-9 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-26-0 CAPLUS


CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 145591-28-2 CAPLUS


CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-29-3 CAPLUS


CN .beta.-Alanine, N-[3-cyclohexyl-2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 145591-30-6 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-31-7 CAPLUS


CN 1-Piperidinepropanamide, N-(3-amino-3-oxopropyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 145591-32-8 CAPLUS


CN Butanoic acid, 4-[[[3-cyclohexyl-2-[[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021



RN 145591-33-9 CAPLUS

CN 1-Piperidinepropanamide, N-(4-amino-4-oxobutyl)-.alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 145591-34-0 CAPLUS

CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]- (9CI) (CA INDEX NAME)




09/ 755,021



RN 145591-35-1 CAPLUS


CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[4-(ethylamino)-4-oxobutyl]-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 145591-36-2 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidin-1-yl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-37-3 CAPLUS

CN 1-Piperidinepropanamide, N-(2-amino-2-oxoethyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-38-4 CAPLUS


CN 1-Piperidinepropanamide, N-[2-(dimethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-39-5 CAPLUS


CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(1-methylethyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-40-8 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-oxo-2-(propylamino)ethyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-41-9 CAPLUS


CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[2-[(2-methylpropyl)amino]-2-oxoethyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 145591-42-0 CAPLUS

CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


09/ 755,021



RN 145591-43-1 CAPLUS  
CN .beta.-Alanine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 145591-44-2 CAPLUS  
CN 1-Piperidinepropanamide, N-[3-(ethylamino)-3-oxopropyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 145591-45-3 CAPLUS  
CN Butanoic acid, 4-[[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-46-4 CAPLUS

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[4-(methylamino)-4-oxobutyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-47-5 CAPLUS


CN 1-Piperidinepropanamide, N-(4-amino-4-oxobutyl)-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 145591-48-6 CAPLUS


CN 1-Piperidinepropanamide, N-[4-(ethylamino)-4-oxobutyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-49-7 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 145591-50-0 CAPLUS

CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 145591-51-1 CAPLUS


CN 1-Piperidinepropanamide, N-[2-(dimethylamino)ethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)

CN(C)CCNC(=O)C(CCN(C1CCCCC1)c2ccc(O)cc2)CCc3ccccc3

CN 1-Piperidinepropanamide, 4-(3-hydroxyphenyl)-3,4-dimethyl-N-[3-(methylamino)-3-oxopropyl]-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




CN 1-Piperidinepropanamide, N-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




CN Glycinamide, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-55-5 CAPLUS

CN Glycine, N-[N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 145591-56-6 CAPLUS

CN Glycinamide, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycyl-N-ethyl- (9CI) (CA INDEX NAME)




RN 145591-61-3 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methoxy-2-oxoethyl ester (9CI) (CA INDEX NAME)




09/ 755,021




RN 145591-62-4 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, pentyl ester (9CI) (CA INDEX NAME)



RN 145591-63-5 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-amino-2-oxoethyl ester (9CI) (CA INDEX NAME)



RN 145591-64-6 CAPLUS


CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(methylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-65-7 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(ethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)





RN 145591-66-8 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-(dimethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)





RN 145591-67-9 CAPLUS

CN 1-Piperidinepropanamide, N-[2-[(cyclohexylmethyl)amino]-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl-.alpha.-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 145591-68-0 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 4-methoxycyclohexyl ester (9CI) (CA INDEX NAME)




RN 145591-69-1 CAPLUS  
 CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-oxo-2-[(phenylmethyl)amino]ethyl ester (9CI) (CA INDEX NAME)

09/ 755,021




RN 145591-70-4 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 1-(acetyloxy)ethyl ester (9CI) (CA INDEX NAME)



RN 145591-71-5 CAPLUS

CN Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (9CI) (CA INDEX NAME)




RN 145603-86-7 CAPLUS

CN Glycine, N-[(2S)-2-[[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 755,021



RN 145603-87-8 CAPLUS

CN Glycine, N-[(2R)-2-[[ (3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145603-88-9 CAPLUS

CN Glycine, N-[(2S)-2-[[ (3S,4S)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, 2-methylpropyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

09/ 755,021



RN 145609-45-6 CAPLUS

CN 1-Piperidinepropanamide, .alpha.-(cyclohexylmethyl)-N-[2-(ethylamino)-2-oxoethyl]-4-(3-hydroxyphenyl)-3,4-dimethyl- (9CI) (CA INDEX NAME)



L3 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1990:111859 CAPLUS

Correction of: 1988:486100

DOCUMENT NUMBER: 112:111859

Correction of: 109:86100

TITLE: Biological evaluation of compounds for their physical dependence potential and abuse liability. X. Drug testing programs of the Committee on Problems of Drug Dependence, Inc. (1986)

AUTHOR(S): Jacobson, Arthur E.

CORPORATE SOURCE: Lab. Chem., Natl. Inst. Diabetes Dig. Kidney Dis., Bethesda, MD, 20892, USA

SOURCE: NIDA Research Monograph (1987), 76(Probl. Drug Depend., 1986), 370-91

CODEN: MIDAD4; ISSN: 0361-8595

09/ 755,021


DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A report is given on the drug-testing programs of the Committee on Problems of Drug Dependence, and new and lit. data are presented from studies of the dependency potential of a large no. of drugs, including epoxymorphinans, phenylmorphans, benzomorphans, methadone-like compds., pethidines, fentanyls, etc.

IT 112239-67-5 112239-69-7  
RL: PRP (Properties)  
(abuse and dependence potential of)

RN 112239-67-5 CAPLUS

CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-4-(1-oxopropyl)-, ethyl ester, hydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 112239-69-7 CAPLUS

CN 1-Piperidineacetic acid, 4-(3-hydroxyphenyl)-4-(1-oxopropyl)-, ethyl ester, ethanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 112239-68-6

CMF C18 H25 N O4




CM 2

CRN 144-62-7

CMF C2 H2 O4






L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1989:648 CAPLUS  
 DOCUMENT NUMBER: 110:648  
 TITLE: Dependence studies of new compounds in the rhesus monkey, rat, and mouse, 1987  
 AUTHOR(S): Aceto, M.; Bowman, E.; Harris, L.; May, E.  
 CORPORATE SOURCE: Med. Coll. Virginia, Virginia Commonw. Univ., Richmond, VA, 23298-0613, USA  
 SOURCE: NIDA Research Monograph (1988), 81(Probl. Drug Depend., 1987), 485-542  
 CODEN: MIDAD4; ISSN: 0361-8595  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB Drug dependence studies of new compds. in lab. animals are summarized. Data on drug dependence studies on known drugs are reviewed.  
 IT 112239-69-7  
 RL: BIOL (Biological study)  
 (dependence on and withdrawal from, evaluation of)  
 RN 112239-69-7 CAPLUS  
 CN 1-Piperidineacetic acid, 4-(3-hydroxyphenyl)-4-(1-oxopropyl)-, ethyl ester, ethanedioate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 112239-68-6  
 CMF C18 H25 N O4




CM 2

CRN 144-62-7  
 CMF C2 H2 O4



09/ 755,021

DOCUMENT NUMBER: 108:106303  
TITLE: Dependence studies of new compounds in the rhesus monkey, rat and mouse (1986)  
AUTHOR(S): Aceto, M. D.; Bowman, E. R.; Harris, L. S.; May, E. L.  
CORPORATE SOURCE: USA  
SOURCE: NIDA Research Monograph (1987), 76 (Probl. Drug Depend., 1986), 392-447  
CODEN: MIDAD4; ISSN: 0361-8595  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Data are presented on the ability of a large no. of drugs to substitute for morphine in a variety of drug dependence-withdrawal models in mice, rats, and monkeys.  
IT 112239-67-5, NIH 10440 112239-69-7, NIH 10454  
RL: BIOL (Biological study)  
(dependence on, potential for)  
RN 112239-67-5 CAPLUS  
CN 1-Piperidinepropanoic acid, 4-(3-hydroxyphenyl)-4-(1-oxopropyl)-, ethyl ester, hydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 112239-69-7 CAPLUS  
CN 1-Piperidineacetic acid, 4-(3-hydroxyphenyl)-4-(1-oxopropyl)-, ethyl ester, ethanedioate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 112239-68-6  
CMF C18 H25 N O4



CM 2

09/ 755,021

CRN 144-62-7  
CMF C2 H2 O4



L3 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1982:28480 CAPLUS

DOCUMENT NUMBER: 96:28480

TITLE: Correlations among certain behavioral, physiological, and biochemical effects of narcotic agonists

AUTHOR(S): Woods, James H.; Katz, Jonathan L.; Young, Alice M.; Medzihradsky, Fedor; Smith, Charles B.

CORPORATE SOURCE: Med. Sch., Univ. Michigan, Ann Arbor, MI, 48109, USA

SOURCE: NIDA Research Monograph (1980), 34, 43-57

CODEN: MIDAD4; ISSN: 0361-8595

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The relative potencies of .kappa.-agonists (ethylketazocine-like drugs such as UM 1070 [57203-00-6], UM 909 [72074-75-0] or ketazocine methane sulfonate [71697-06-8]) and .mu.-agonists (morphine-like drugs such as fentanyl citrate [990-73-8], etorphine-HCl [13764-49-3], or UM 1176 [72074-73-8]) in inhibiting the elec.-induced twitch in isolated mouse vas deferens and guinea-pig ileum were compared and correlated to their relative potencies in displacing bound 3H-labeled etorphine from rat cerebrum membrane prepn. or to their potencies in pptg. or suppressing abstinence in morphine-dependent rhesus monkeys. Differences in the relative potencies of .kappa.- and .mu.-agonists on the ileum and vas deferens preps. failed to distinguish the relative agonists types. However, correlations of the effects of either type of agonist in these preps. with displacement of bound 3H-labeled etorphine did distinguish between .mu.- and .kappa.-agonists. Correlations among effects in the vas deferens or ileum with effects in the 14-h withdrawn morphine-dependent monkey displayed differentiations between smooth muscle preps. but not agonist types; slopes of regression lines of in vivo effects in the ileum were steeper than with effects in the vas deferens, indicating that the effects in the ileum overestimate while effects in the vas deferens underestimate the in vivo potencies of these agonists. In another correlation study, Meperidine-HCl [50-13-5] and its analog, UM 1170 [74716-70-4], suppressed abstinence in the morphine-withdrawn monkey but failed to displace etorphine from isolated brain prepn., indicating that the narcotic action of these 2 compds. was mediated by distinctive recognition sites.

IT 80264-72-8

RL: PRP (Properties)

(behavioral and biochem. and physiol. effects of, correlation studies of)


RN 80264-72-8 CAPLUS

CN 1-Propanone, 1-[1-(2-ethoxyethyl)-4-(3-hydroxyphenyl)-4-piperidinyl]-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 80264-71-7


CMF C18 H27 N O3



CM 2

CRN 144-62-7

CMF C2 H2 O4



L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1964:454790 CAPLUS  
 DOCUMENT NUMBER: 61:54790  
 ORIGINAL REFERENCE NO.: 61:9471d-g  
 TITLE: 1-Aralkyl-4-(3-hydroxyphenyl)-4-propionylpiperidines  
 PATENT ASSIGNEE(S): C. H. Boehringer Sohn.  
 SOURCE: 17 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1316888		19630201	FR	
BE 614689			BE	
FR M2411			FR	

PRIORITY APPLN. INFO.: DE 19610306


GI For diagram(s), see printed CA Issue.  
 AB 4-(3-Hydroxyphenyl)-4-propionylpiperidine (I), which is prep'd. from m-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CN (II) and tosylbis(.beta.-chloroethyl)amine (III), is treated with aralkyl halides to give compds. of the general formula IV. Thus, a mixt. of 147 g. II, 196 g. III, 1500 ml. PhMe, and 85 g. NaNH<sub>2</sub> is refluxed 1 hr. to give 65% 1-tosyl-4-(3-methoxyphenyl)-4-cyanopiperidine (V), m. 167.degree.. V (222 g.) is treated with the Grignard reagent prep'd. from 374 g. EtI and 57.5 g. Mg to give 4-[1-tosyl-4-(3-methoxyphenyl)]piperidylethyl ketimine (VI). A mixt. of 246 g. VI, 1500 ml. 48% HBr, and 246 g. PhOH is refluxed 3 hrs. to give 70% I, m. 222.degree. (EtOH). A mixt. of 2.32 g. I, 1.26 g. NaHCO<sub>3</sub>, 2.2 g. Ph(CH<sub>2</sub>)<sub>3</sub>Br, and 25 ml. EtOH is refluxed 48 hrs. to give 71.5% 1-(3-phenylpropyl)-4-(3-hydroxyphenyl)-4-propionylpiperidine, m. 171.degree. (EtOH); HCl salt m. .apprx.95.degree.. Similarly prep'd. are the following IV (R and m.p. HCl salt given): PhCH:CHCH<sub>2</sub>, 228.degree. (EtOH-ether); 3-(2-furyl)propyl, 140.degree. (decompn.); p-MeC<sub>6</sub>H<sub>4</sub>CH:CH, 168.degree. (alc.-ether); 3-(4-pyridyl)propyl (m. 108-9.degree.), --; MeCPh:CHCH<sub>2</sub>, 203.degree. (alc.-ether); Ph(CH<sub>2</sub>)<sub>4</sub>, 159-61.degree. (alc.-ether); PhCH:CHCH<sub>2</sub>CH<sub>2</sub>, 177-9.degree. (alc.-ether). Also prep'd. is

the methanesulfonate, m. 185-9.degree., of IV (R = PhCH:CHCH<sub>2</sub>).

IT 95318-89-1, 1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride  
(prepn. of)

RN 95318-89-1 CAPLUS

CN 1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride (7CI) (CA INDEX NAME)



⊙ HCl

L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1964:425328 CAPLUS  
DOCUMENT NUMBER: 61:25328  
ORIGINAL REFERENCE NO.: 61:4321f-h,4322a  
TITLE: Piperidine compounds  
PATENT ASSIGNEE(S): Dr. Karl Thomae, G.m.b.H  
SOURCE: 7 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: Unavailable  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 950813		19640226	GB	

PRIORITY APPLN. INFO.: DE 19610306

GI For diagram(s), see printed CA Issue.

AB The title compds. have marked analgesic action on the central nervous system. NaHCO<sub>3</sub> (12.6 g.) and 13 g. furfuryl chloride were added to 23.3 g. 4-(3-hydroxyphenyl)-4-propionylpiperidine and reflux 1 hr. in 100 cc. HCONMe<sub>2</sub>-250 cc. abs. tetrahydrofuran. The solvents were removed in vacuo, the residue dissolved in CHCl<sub>3</sub>, the soln. washed 3 times with 300 cc. H<sub>2</sub>O, dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent removed to leave 1-furfuryl-4-(3-hydroxyphenyl)-4-propionylpiperidine (I), m. 116.degree. (Me<sub>2</sub>CO-cyclohexane); HCl salt m. 192.degree.. Similarly prepd. are the following piperidine-HCl (m.p. given): 1-tetrahydrofurfuryl-4-(3-hydroxyphenyl)-4-propionyl, 144-6.degree.; 1-(2-propoxy-ethyl)-4-(3-hydroxyphenyl)-4-propionyl, 122.degree.; 1-(2-ethoxy-ethyl)-4-(3-hydroxyphenyl)-4-propionyl, 128.degree.; 1-(2-ethoxy-propyl)-4-(3-hydroxyphenyl)-4-propionyl, 157-9.degree.; 1-furfuryl-4-(3-hydroxyphenyl)-4-acetyl, 194.degree.; 1-furfuryl-4-(3-hydroxyphenyl)-4-butyryl, 213.degree.; 1-(5-methylfurfuryl)-4-(3-hydroxyphenyl)-4-propionyl, 164.degree.; 1-furfuryl-4-(3-methoxyphenyl)-4-propionyl, 146.degree., and 1-furfuryl-4-(3-acetoxyphenyl)-4-propionyl, 131.degree.. The title compds. are kept in ampuls, or added to suppositories, drop solns., and tablets.


IT 88826-86-2, 1-Propanone, 1-[1-(2-ethoxyethyl)-4-(m-hydroxyphenyl)-

09/ 755,021

4-piperidyl]-, hydrochloride **95318-89-1**, 1-Propanone,  
1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride  
**95318-97-1**, 1-Propanone, 1-[1-(2-ethoxypropyl)-4-(m-hydroxyphenyl)-  
4-piperidyl]-, hydrochloride  
(prepn. of)

RN 88826-86-2 CAPLUS


CN 1-Propanone, 1-[1-(2-ethoxyethyl)-4-(m-hydroxyphenyl)-4-piperidyl]-,  
hydrochloride (7CI) (CA INDEX NAME)



HCl

RN 95318-89-1 CAPLUS


CN 1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-,  
hydrochloride (7CI) (CA INDEX NAME)



HCl

RN 95318-97-1 CAPLUS


CN 1-Propanone, 1-[1-(2-ethoxypropyl)-4-(m-hydroxyphenyl)-4-piperidyl]-,  
hydrochloride (7CI) (CA INDEX NAME)



⊗ HCl

L3 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1964:75333 CAPLUS  
 DOCUMENT NUMBER: 60:75333  
 ORIGINAL REFERENCE NO.: 60:13228g-h  
 TITLE: Hydrazone hydrolysis  
 INVENTOR(S): Loev, Bernard  
 PATENT ASSIGNEE(S): Smith Kline & French Laboratories  
 SOURCE: 2 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 3113971		19631210	US	19600415
AB	Hydrazones are hydrolyzed with excess picric acid soln. at room temp. to give the corresponding aldehydes or ketones. A mixt. of 13.5 g. Me 2-pyridyl ketone hydrazone in 150 ml. EtOH and 25.0 g. picric acid in EtOH is heated 2 min. at 50.degree., cooled, and filtered, and the EtOH evapd. to give Me 2-pyridyl ketone. Similarly prepd. are BzH, BzPh, EtCOMe, cyclopropyl Me ketone, cyclohexanone, camphor, n-heptaldehyde, furfural, fluorenone, and 3-methyl-5-acetonylpyrazole.				
IT	95318-89-1, 1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride (prepn. of)				
RN	95318-89-1 CAPLUS				
CN	1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride (7CI) (CA INDEX NAME)				



HCl

L3 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1964:75332 CAPLUS  
 DOCUMENT NUMBER: 60:75332  
 ORIGINAL REFERENCE NO.: 60:13228c-g  
 TITLE: 4-Aryl-4-propionylpiperidine derivatives  
 PATENT ASSIGNEE(S): Dr. Karl Thomae G.m.b.H.  
 SOURCE: 9 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 948874		19640205	GB	

PRIORITY APPLN. INFO.: DE 19610306

GI For diagram(s), see printed CA Issue.

AB Compds. of the general formula I, wherein R is an alkyl or alkenyl group contg. 3 or 4 C atoms and substituted by an aromatic group at the 3 or 4 position, have a pronounced analgesic action with a marked antagonism to morphine, and were prepd. by alkylating I (R = H) with appropriate halides in the presence of a weak base. To a cooled and stirred soln. of 147 g. m-MeOC6H4CH2CN and 196 g. p-MeC6H4SO3N(CH2CH2Cl)2 in 1500 ml. abs. PhMe was gradually added 83 g. powd. NaNH2 at 40-5.degree., the mixt. refluxed 1 hr. and cooled with ice-H2O, and 120 ml. H2O added dropwise with stirring at 0-5.degree. followed by an addnl. 1 l. H2O. The ppt. was filtered off and washed (H2O and MeOH) to give 240 g. 1-tosyl-4-(3-methoxyphenyl)-4-cyanopiperidine (II), m. 167.degree.. A Grignard reagent was prepd. from 374 g. EtI and 57.5 g. Mg in 750 ml. Et2O, the Et2O evapd. under N, and the residue in 750 ml. abs. C6H6 added to 222 g. II. The reaction mixt. was stirred 16 hrs. under reflux at 90.degree., cooled with ice-H2O, and stirred into 3.5 kg. crushed ice and 350 g. NH4Cl, C6H6 layer sepd., the aq. layer extd. twice with 500 ml. C6H6, and the combined exts. dried (Na2SO4) and C6H6 evapd. in vacuo to give 245 g. crude 1-tosyl-4-(3-methoxyphenyl)-4-piperidylethyl ketimine (II) as a honey-yellow sirup which crystd. on standing. II (246 g.) was refluxed 3 hrs. with 1500 ml. 48% HBr and 246 g. PhOH, cooled, dild. with 1.5 l. H2O, and extd. with Et2O to remove PhOH, the aq. soln. concd. in vacuo, the residue satd. with Me2CO, and the ppt. filtered off and washed (Me2CO) to give 200 g. crude hydrobromide, a soln. of which in 400 ml. H2O (C) cooled to 20.degree. and treated with 50 ml. concd. NH4OH with stirring, and the ppt. filtered off and washed (H2O) gave 97 g. I (R = H) (III), m. 222.degree. (EtOH). A mixt. of 2.32 g. III, 1.26 g. NaHCO3, and 2.2 g. 3-phenylpropyl bromide was refluxed 48 hrs. with stirring in 25 ml. EtOH, EtOH evapd., the residue extd. with 50 ml. CHCl3, the ext. washed (H2O)




and dried (Na<sub>2</sub>SO<sub>4</sub>), and CHCl<sub>3</sub> evapd. in vacuo to give 2.5 g. I (R = 3-phenylpropyl) (IV), m. 171.degree. (EtOH). IV.HCl, m. 95.degree. (hygroscopic), was prepd. as usual from IV with alc.-HCl. Similarly prepd. were various I.HCl (R, m.p., and % yield given) (unless otherwise stated, a mixt. of HCONMe<sub>2</sub> and tetrahydrofuran (10:25) was used as the solvent for these condensations and the compds. were crystd. from EtOH-Et<sub>2</sub>O mixt.). Cinnamyl, 228.degree., 51.5 (methanesulfonate m. 185-9.degree.); 3-(2-furyl)propyl, 140.degree. (decompn., sintered 85.degree.), 45; p-methylcinnamyl, 168.degree., 57.5; 3-(4-pyridyl) -- [base m. 108-9.degree. (EtOH-petr. ether)], 27; 3-methyl-3-phenylallyl, 203.degree.. 30; 4-phenylbutyl, 159-61.degree., 72; 2-styrylethyl, 177-9.degree., 42.5.degree..

IT 95318-89-1, 1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride  
(prepn. of)

RN 95318-89-1 CAPLUS

CN 1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride (7CI) (CA INDEX NAME)



HCl

L3 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1963:66433 CAPLUS  
 DOCUMENT NUMBER: 58:66433  
 ORIGINAL REFERENCE NO.: 58:11334a-d  
 TITLE: 1-Alkyl-4-phenyl-4-acylpiperidines  
 PATENT ASSIGNEE(S): C. H. Boehringer Sohn.  
 SOURCE: 17 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 614688		19620905	BE	
FR 1316887			FR	
FR M2025			FR	

PRIORITY APPLN. INFO.: DE 19610306

GI For diagram(s), see printed CA Issue.

AB I, in which R is H, Me, or Ac, R<sub>1</sub> is Me, Et, or Pr, and R<sub>2</sub> is a furfuryl, tetrahydrofurfuryl, or an alkoxyalkyl radical, have analgesic and antitussive properties. 4-(3-Hydroxyphenyl)-4-propionylpiperidine (23.3 g.), 12.6 g. NaHCO<sub>3</sub>, and 13 g. furfuryl chloride are mixed with 100 ml. HCONMe<sub>2</sub> and 250 ml. abs. tetrahydrofuran, the mixt. refluxed 1 hr., the solvent distd. in vacuo, the residue washed with CHCl<sub>3</sub>, the CHCl<sub>3</sub> soln. washed with H<sub>2</sub>O, dried, and the CHCl<sub>3</sub> evapd. to give 1-furfuryl-4-(3-


hydroxyphenyl)-4-propionylpiperidine (II), m. 116.degree.

(Me2CO-cyclohexane). II is dissolved in 500 ml. EtOH and the soln. treated with alc. HCl to give 27 g. II.HCl, m. 192.degree. (alc.-ether), 77% yield. Similarly prepd. are I (R, R1, R2, HCl salt m.p. (alc.-Et2O) given): H, Et, tetrahydrofurfuryl, 144-6.degree.; H, Et, PrOCH2CH2, 122.degree.; H, Et, EtOCH2CH2, 128.degree.; H, Et, Me(EtO)-CHCH2, 157-9.degree.; H, Me, furfuryl, 194.degree.; H, Pr, furfuryl, 213.degree.; H, Et, 5-methylfurfuryl, 164.degree.; Me, Et, furfuryl, 146.degree.; and Ac, Et, furfuryl, 131.degree..

IT 88826-86-2, 1-Propanone, 1-[1-(2-ethoxyethyl)-4-(m-hydroxyphenyl)-4-piperidyl]-, hydrochloride 95318-89-1, 1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride 95318-97-1, 1-Propanone, 1-[1-(2-ethoxypropyl)-4-(m-hydroxyphenyl)-4-piperidyl]-, hydrochloride (prepn. of)

RN 88826-86-2 CAPLUS


CN 1-Propanone, 1-[1-(2-ethoxyethyl)-4-(m-hydroxyphenyl)-4-piperidyl]-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 95318-89-1 CAPLUS

CN 1-Propanone, 1-[4-(m-hydroxyphenyl)-1-(2-propoxyethyl)-4-piperidyl]-, hydrochloride (7CI) (CA INDEX NAME)




HCl

RN 95318-97-1 CAPLUS

CN 1-Propanone, 1-[1-(2-ethoxypropyl)-4-(m-hydroxyphenyl)-4-piperidyl]-, hydrochloride (7CI) (CA INDEX NAME)

09/ 755,021



HCl

=> d his

(FILE 'HOME' ENTERED AT 09:49:45 ON 03 OCT 2003)

FILE 'REGISTRY' ENTERED AT 09:51:13 ON 03 OCT 2003

L1 STRUCTURE UPLOADED

L2 624 S L1 FUL

FILE 'CAPLUS' ENTERED AT 09:51:52 ON 03 OCT 2003

L3 37 S L2

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.00

320.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-24.09

-24.09

STN INTERNATIONAL LOGOFF AT 09:57:39 ON 03 OCT 2003